Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39820

Clever Leaves Holdings Inc.

(Exact name of registrant as specified in its charter)


British Columbia, Canada						Not Applicable
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

Bodega 19-B Parque Industrial Tibitoc P.H, Tocancipá - Cundinamarca, Colombia						N/A
(Address of principal executive offices)						(Zip Code)

(Registrant’s telephone number, including area code): (561) 634-7430

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common shares without par value

CLVR

The Nasdaq Stock Market LLC

Warrants, each warrant exercisable for 1/30th common share at an exercise price of $11.50

CLVRW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

Emerging growth company

☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of registrant’s common shares outstanding as of November 7, 2023 was 1,745,152.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

TABLE OF CONTENTS


		Page
	PART I - FINANCIAL INFORMATION
ITEM 1.	Financial Statements of Clever Leaves Holdings Inc. (Unaudited)
	Condensed Consolidated Statements of Financial Position as of September 30, 2023 and December 31, 2022	4
	Condensed Consolidated Statements of Operations for the Three and Nine months ended September 30, 2023 and 2022	5
	Condensed Consolidated Statements of Shareholders' Equity for the Three and Nine months ended September 30, 2023 and 2022	6
	Condensed Consolidated Statements of Cash Flows for the Nine months ended September 30, 2023 and 2022	8
	Notes to Unaudited Condensed Consolidated Financial Statements	9

ITEM 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	30

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risks	45

ITEM 4.	Controls and Procedures	46

	PART II - OTHER INFORMATION
ITEM 1.	Legal Proceedings	48
ITEM 1A.	Risk Factors	48
ITEM 5.	Other Information	49
ITEM 6.	Exhibits	50
	SIGNATURES	51

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Form 10-Q”) includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. You should not place undue reliance on such statements because they are subject to numerous risks and uncertainties which are difficult to predict and many of which are beyond our control and could cause our actual results to differ from the forward-looking statements. Forward-looking statements include information concerning our possible or assumed future results of operations, including descriptions of our business strategy. These statements are often, but not always, made through the use of words or phrases such as “believe,” “anticipate,” “could,” “may,” “would,” “should,” “intend,” “plan,” “potential,” “predict,” “forecast,” “will,” “expect,” “budget,” “contemplate,” “believe,” “estimate,” “continue,” “project,” “positioned,” “strategy,” “outlook” and similar expressions. You should read statements that contain these words carefully because they:

•discuss future expectations;

•contain projections of future results of operations or financial condition; or

•state other “forward-looking” information.

All such forward-looking statements are based on our current expectations and involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. We believe it is important to communicate our expectations to our security holders. However, there may be future events that we are not able to predict accurately or over which we have no control. The risk factors and cautionary language discussed in this Part I, Item 1A, “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2022 (the “Annual Report” or “2022 Form 10-K”) provide examples of risks, contingencies, uncertainties, and events that may cause our actual results to differ materially from the expectations described by us in such forward-looking statements, including among other things:

•our ability to continue as a going concern;

•our ability to maintain the listing of our securities on Nasdaq;

•changes adversely affecting the industry in which we operate;

•our restructuring plans;

•the availability or terms of future financing;

•our ability to achieve our business strategies;

•general economic conditions, including the ongoing military conflict between Russia and Ukraine (and resulting sanctions) on the global economy, global financial markets and our business;

•regional political and economic conditions, including the ongoing war between Israel and Hamas, as well as emerging market conditions;

•the impact and magnitude of rising energy costs;

•the impact and magnitude of inflation and currency fluctuations;

•the regulation and legalization of adult-use, recreational cannabis;

•our ability to retain our key employees; and

•other factors that are more fully discussed in Part I, Item 1A of the "2022 Form 10-K" under the heading “Risk Factors”, and those discussed in other documents we file with the SEC.

These risks could cause actual results to differ materially from those implied by the forward-looking statements contained in this Form 10-Q.

All forward-looking statements included herein attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. These forward-looking statements speak only as of the date of this Form 10-Q. Except to the extent required by applicable laws and regulations, we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

This Form 10-Q contains estimates, projections and other information concerning our industry, our business, and the markets for our products. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

ITEM 1. FINANCIAL STATEMENTS

CLEVER LEAVES HOLDINGS INC.

Condensed Consolidated Statements of Financial Position

(Amounts in thousands of U.S. Dollars, except share and per share data)

(Unaudited)


		As of		As of
	Note	September 30, 2023		December 31, 2022
Assets
Current:
Cash and cash equivalents		$	6,472	$	12,449
Restricted cash		66		439
Accounts receivable, net		1,746		2,252
Prepaids, deposits and other receivables	6	1,941		2,708

Inventories, net	5	7,709		8,399
Total current assets		17,934		26,247

Investment – Cansativa	7	1,896		5,679
Property, plant and equipment, net of accumulated depreciation of $8,389 and $7,120 for September 30, 2023 and December 31, 2022, respectively	9	12,752		13,963
Assets held for sale - Land		1,500		1,500
Intangible assets, net	8	2,821		3,354

Operating lease right-of-use assets, net	18	820		1,303
Other non-current assets		54		52
Total Assets		$	37,777	$	52,098

Liabilities
Current:
Accounts payable		$	2,088	$	2,299
Accrued expenses and other current liabilities		3,225		4,238

Loans and borrowings, current portion	10	477		465
Warrant liability		108		113
Operating lease liabilities, current portion	18	512		1,239
Deferred revenue		437		1,072
Total current liabilities		6,847		9,426

Loans and borrowing — long-term	10	859		1,065

Operating lease liabilities — long-term	18	366		1,087

Other long-term liabilities		16		112
Total Liabilities		$	8,088	$	11,690

Contingencies and commitments

Shareholders’ equity
Preferred shares, without par value, unlimited shares authorized, nil shares issued and outstanding for each of September 30, 2023 and December 31, 2022		—		—
Common shares, without par value, unlimited shares authorized: 1,726,145 and 1,454,559 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	11	—		—
Additional paid-in capital		223,407		221,313
Accumulated deficit		(193,718)		(180,905)
Total shareholders' equity		29,689		40,408
Total liabilities and shareholders' equity		$	37,777	$	52,098

See accompanying notes to the condensed consolidated financial statements

CLEVER LEAVES HOLDINGS INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Amounts in thousands of U.S. Dollars, except share and per share data)

(Unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,
	Note	2023		2022		2023		2022
Revenue, net	15	$	3,820	$	2,867	$	12,779	$	12,008



Cost of sales		(1,878)		(1,568)		(5,877)		(5,635)
Gross profit		1,942		1,299		6,902		6,373

Expenses
General and administrative	12	4,155		5,442		14,327		18,865
Sales and marketing		582		615		1,600		2,075
Research and development		292		343		907		1,114
Restructuring expenses	13	—		(82)		—		3,761
Goodwill impairment				19,000				19,000
Depreciation and amortization		290		305		750		950
Total expenses		5,319		25,623		17,584		45,765

Loss from operations		(3,377)		(24,324)		(10,682)		(39,392)

Other Expense (Income), net
Interest and amortization of debt issuance cost		5		(58)		23		2,696
Gain on remeasurement of warrant liability	11	(60)		(196)		(5)		(2,009)
Gain on investment	7	—		—		—		(6,851)
Investment impairment	7	3,705		—		3,705		—
Loss on debt extinguishment, net	10	—		—		—		2,263

Foreign exchange loss		275		669		297		1,144
Other (income) expense, net		(31)		102		(19)		111
Total other expenses (income), net		3,894		517		4,001		(2,646)

Loss before income taxes and equity investment loss		(7,271)		$	(24,841)	$	(14,683)	$	(36,746)

Deferred income tax (recovery)		—		(6,650)		—		(6,650)

Equity investment share of loss		—		—		—		64
Loss from continuing operations		$	(7,271)	$	(18,191)	$	(14,683)	$	(30,160)
Income (loss) from discontinued operations		2,133		(1,972)		1,869		(7,189)
Net loss		$	(5,138)	$	(20,163)	$	(12,814)	$	(37,349)
Net loss per share:
Basic and diluted from continuing operations	17	$	(4.60)	$	(12.93)	$	(9.70)	$	(24.70)
Basic and diluted from discontinued operations		1.35		(1.41)		1.23		(5.90)
Net loss per share		$	(3.25)	$	(14.33)	$	(8.47)	$	(30.59)
Weighted-average common shares outstanding:		1,580,456		1,407,419		1,513,575		1,221,107
Basic and diluted	17	(3.25)		(14.33)		(8.47)		(30.59)

See accompanying notes to the condensed consolidated financial statements.

CLEVER LEAVES HOLDINGS INC.

Condensed Consolidated Statements of Shareholders’ Equity

(Amounts in thousands of U.S. Dollars, except share and per share data)

(Unaudited)


	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Total Shareholders’ Equity
	Shares	Amount		Amount		Amount		Amount
Balance at December 31, 2021	886,860	$	—	$	187,510	$	(114,740)	$	72,770
Issuance of common shares, gross	368,252	—		23,400		—		23,400
Issuance of common shares upon vesting RSUs	8,248	—		—		—		—
Stock option exercise	3,870	—		22		—		22
Stock-based compensation expense	—	—		500		—		500
Equity issuance costs	—	—		(1,177)		—		(1,177)
Beneficial conversion feature of Convertible Note	—	—		1,749		—		1,749
Conversion of Convertible Note to common shares	20,233	—		1,324		—		1,324
Net loss	—	—		—		(16,140)		(16,140)
Balance at March 31, 2022	1,287,463	$	—	$	213,328	$	(130,880)	$	82,448
Issuance of common shares upon vesting RSUs	1,330	—		—		—		—

Stock option exercise	1,186	—		—		—		—

Stock-based compensation expense	—	—		1,148		—		1,148
Conversion of Convertible Note to common shares	30,000	—		2,039		—		2,039
Net loss	—	—		—		(1,046)		(1,046)
Balance at June 30, 2022	1,319,979	$	—	$	216,515	$	(131,926)	$	84,589
Net loss	—	—		$	—	$	(20,163)	$	(20,163)
Issuance of common shares upon vesting RSUs	828	—		—		—		—

Stock-based compensation expense	—	—		958		—		958

Issuance of common shares - gross	131,573	—		4,286		—		4,286
Equity issuance costs	—	—		(168)		—		(168)

Balance at September 30, 2022	1,452,380	$	—	$	221,591	$	(152,089)	$	69,502


	Note	Common Stock			Additional Paid-in Capital		Accumulated Deficit		Total Shareholders’ Equity
		Shares	Amount		Amount		Amount		Amount
Balance at December 31, 2022		1,454,559	$	—	$	221,313	$	(180,905)	$	40,408
Issuance of common shares upon vesting RSUs		12,350	—		—		—		—
Stock-based compensation expense		—	—		468		—		468
Equity issuance costs		—	—		(25)		—		(25)
Net loss		—	—		—		(4,081)		(4,081)
Balance at March 31, 2023		1,466,909	$	—	$	221,756	$	(184,986)	$	36,770
Issuance of common shares upon vesting RSUs	14	4,587	—		—		—		—

Stock-based compensation expense	12	—	—		433		—		433
Issuance of common shares - gross		51,986	—		438		—		438
Equity issuance costs		—	—		(97)		—		(97)


Net loss		—	—		—		(3,595)		(3,595)
Balance at June 30, 2023		1,523,482	$	—	$	222,530	$	(188,581)	$	33,949
Issuance of common shares upon vesting RSUs		738	—		—		—		—

Stock-based compensation expense		—	—		52		—		52
Issuance of common shares - gross		201,912	—		903		—		903
Equity issuance costs		—	—		(77)		—		(77)
Round off due to reverse split		13	—		—				—

Net loss		—	—		—		(5,138)		(5,138)
Balance at September 30, 2023		1,726,145	$	—	$	223,407	$	(193,718)	$	29,689

The above Condensed Consolidated Statements of Stockholders’ Equity reflects a 1 for 30 reverse stock split effective August 25, 2023, see Note 2 for further information

See accompanying notes to the condensed consolidated financial statements.

CLEVER LEAVES HOLDINGS INC.

Condensed Consolidated Statements of Cash Flows

(Amounts in thousands of U.S. Dollars)

(Unaudited)


		Nine Months Ended September 30,
		2023	2022
Cash Flow from Operating Activities:
Loss from continuing operations		(14,683)	(30,160)
Gain (loss) from discontinued operations		1,869	(7,189)
Net loss		(12,814)	(37,349)
Adjustments to reconcile to net cash used in operating activities:
Depreciation and amortization		1,933	2,935
Gain on sale of fixed assets		(2,825)	—
Amortization of debt discount and debt issuance cost		—	1,949
Inventory provision	5	591	3,822
Restructuring and related costs	13	—	3,791
Gain on remeasurement of warrant liability	11	(5)	(2,009)
Intangible asset impairment		—	19,000
Deferred tax recovery		—	(6,650)
Amortization of right of use asset	18	483	128
Foreign exchange loss		341	1,420
Stock-based compensation expense	14	954	2,606
Investment impairment		3,705	—
Equity investment share of loss		—	64
Gain on investment	7	—	(6,851)
Loss on debt extinguishment, net	10	—	2,263

Other non-cash expense, net		—	600
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable		506	(369)
Decrease (increase) in prepaid expenses and other receivables	6	767	(466)
(Increase) decrease in other non-current assets		(638)	555
(Decrease) in lease liability	18	(788)	—
Decrease (increase) in inventory		99	(5,067)
(Decrease) in accounts payable and other current liabilities		(2,178)	(4,756)
(Decrease) increase in accrued and other non-current liabilities		(96)	415
Net cash used in operating activities		(9,965)	(23,969)

Cash Flow from Investing Activities:
Proceeds from sale of fixed assets		2,825	—
Purchase of property, plant and equipment		(187)	(1,856)
Proceeds from partial sale of equity method of investment		—	2,498
Net cash provided by investing activities		2,638	642

Cash Flow from Financing Activities:

Repayment of debt	10	(323)	(22,897)
Other borrowings		—	73

Proceeds from issuance of shares	11	1,340	27,686
Equity issuance costs	11	(199)	(1,345)


Stock option exercise		—	22
Net cash provided by financing activities		818	3,539
Effect of exchange rate changes on cash, cash equivalents & restricted cash		159	(304)
Decrease in cash, cash equivalents & restricted cash		(6,350)	(20,092)
Cash, cash equivalents & restricted cash, beginning of period (a)		12,888	37,699
Cash, cash equivalents & restricted cash, end of period (a)		6,538	17,607

(a) These amounts include restricted cash of $66 and $454 as of September 30, 2023 and September 30, 2022, respectively, which are comprised primarily of cash on deposits for certain lease arrangements.

See accompanying notes to the condensed consolidated financial statements.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

1. CORPORATE INFORMATION

Clever Leaves Holdings Inc., (the “Company”) is a multi-national U.S. based holding company focused on cannabinoids. In addition to the cannabinoid business, the Company is also engaged in the non-cannabinoid business of nutraceutical and other natural remedies and wellness products. The Company is incorporated under the Business Corporations Act of British Columbia, Canada.

The mailing address of the Company's principal executive office is Bodega 19-B Parque Industrial Tibitoc P.H, Tocancipá - Cundinamarca, Colombia.

2. BASIS OF PRESENTATION

The accompanying interim condensed consolidated financial statements (“Financial Statements”) are unaudited. These Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of regulation S-X. Accordingly, they do not include all disclosures required for annual financial statements. These Financial Statements reflect all adjustments, which, in the opinion of the management, are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances have been eliminated. All adjustments were of a normal recurring nature. Interim results are not necessarily indicative of results to be expected for the full year.

The Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Company’s subsidiaries and respective ownership percentage has not changed from the year ended December 31, 2022.

These Financial Statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2022, included in its Annual Report on Form 10-K, as filed with the SEC on March 30, 2023 (the "Annual Report").

On August 24, 2023, the Company effected a one-for-thirty reverse share split of its common shares ((the “Reverse Share Split”), effective as of 5:00 p.m. Eastern Time on August 24, 2023 (the “Effective Time”). All share and per share information in these financial statements has been retroactively adjusted to reflect the Reverse Share Split. No fractional shares were issued in connection with the Reverse Share Split. Instead, each fractional share remaining after completion of the Reverse Share Split that was less than half of a whole share was rounded down and canceled without consideration to the holders thereof and each fractional share that was at least half of a whole share was rounded up to one whole share.

Discontinued Operations

During the fiscal year 2022, the Company undertook various strategic initiatives aimed at reducing costs, improving organizational efficiency, and optimizing its business model. As part of these initiatives, the Company implemented several restructuring activities.

Additionally, in December 2022, the Company made the decision to shut down its Portugal operations in order to preserve cash. In January 2023, the Company further approved the wind-down of its entire Portuguese operations to enhance operating margin and focus solely on cannabis cultivation and production in Colombia. As part of this restructuring plan, the Company has completed the cessation of its Portuguese flower cultivation, post-harvest processes, and manufacturing activities. Subsequently, the post harvest facility has been sold and preparations are currently underway for the sale of the farm land with the objective of concluding the sale by March 31, 2024.

Considering the nature and extent of the restructuring activities undertaken, in accordance with Accounting Standards Codification (ASC) 205, Presentation of Financial Statements, the Company has determined that these operations meet the "discontinued operations" criteria as of September 30, 2023. As a result, the condensed consolidated statements of financial position, the condensed consolidated statements of operations, the condensed consolidated statements of cash flows, and the notes to the consolidated financial statements have been restated for all periods presented to reflect the discontinuation of these operations in accordance with ASC 205.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

Please refer to Note 19, "Discontinued Operations," for further details regarding the discontinued businesses. The discussion in the notes to these financial statements, unless otherwise noted, pertains solely to the Company's continuing operations.

Going Concern

These interim condensed financial statements have been prepared in accordance with U.S. GAAP, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve months from the date of issue.

As shown in the accompanying interim condensed financial statements, the Company had an accumulated deficit as of September 30, 2023, as well as operating losses and negative cash flows from operations since inception and expects to continue to incur net losses for the foreseeable future until such time that it can generate significant revenue from the sale of its available inventories.

At September 30, 2023, the Company had cash and cash equivalents of $6,472. As of September 30, 2023, the Company’s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the date the consolidated financial statements were issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company’s ability to execute its operating plans through 2023 and beyond depends on its ability to obtain additional funding, which may include several initiatives such as raising capital, reducing working capital, and monetizing non-core assets, to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all.

Principles of Consolidation

The Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company's significant accounting policies are disclosed in its audited consolidated financial statements for the year ended December 31, 2022, included in the Annual Report. Except as noted below, there have been no other changes in the Company's significant accounting policies as discussed in the Annual Report.

Use of Accounting Estimates

The preparation of these Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the Financial Statements and accompanying notes in the reported period. These estimates include, but are not limited to, allowance for doubtful accounts, inventory valuation, determination of fair value of stock-based awards and estimate of incremental borrowing rate for determining the present value of future lease payments, intangible assets, useful lives of property and equipment, revenue recognition and income taxes and related tax asset valuation allowances. While the significant estimates made by management in the preparation of the consolidated financial statements are reasonable, prudent, and evaluated on an ongoing basis, actual results may differ materially from those estimates.

Recently Adopted Accounting Pronouncements

ASU No. 2016-13- Credit Losses on Financial Instruments (Topic 326)

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses for certain financial instruments and financial assets. For trade receivables, we are required to estimate lifetime expected credit losses. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023. We have adopted the provisions of Accounting Standards Update (ASU) No. 2016-13, Credit Losses on Financial Instruments (Topic 326). After careful consideration and analysis, we have determined that the adoption of this pronouncement has not had a material impact on our financial reporting. Therefore, our financial statements and disclosures have not been significantly affected by the adoption of this standard.

4. FAIR VALUE MEASUREMENTS

The following table provides the fair value measurement hierarchy of the Company’s assets and liabilities, except for those assets and liabilities that are short term in nature and approximate the fair values, as of the periods presented:


	Level 1		Level 2		Level 3		Total

As of September 30, 2023
Assets:
Investment – Cansativa	—		—		1,896		1,896
Total Assets	$	—	$	—	$	1,896	$	1,896
Liabilities:
Loans and borrowings	—		1,336		—		1,336
Warrant liability	—		—		108		108

Total Liabilities	$	—	$	1,336	$	108	$	1,444

As of December 31, 2022
Assets:
Investment – Cansativa	—		—		5,679		5,679
Total Assets	$	—	$	—	$	5,679	$	5,679
Liabilities:
Loans and borrowings	—		1,530		—		1,530
Warrant liability	—		—		113		113
Total Liabilities	$	—	$	1,530	$	113	$	1,643

Investment – Cansativa

Our investment in Cansativa's equity securities does not have a “readily determinable fair value,” or is not traded in a verifiable public market. The Company accounted for this investment under ASC 321, Investments - Equity Securities. The Company used the practical expedient available under ASU 2016-01, the cost method investment which presents and carries this investment using the alternative measurement method which is cost minus impairment, if any, plus or minus changes resulting from observable price changes in “orderly transactions,” as defined in ASC 321, for the identical or a similar investment of the same issuer. The Company periodically reviews the investments for other than temporary declines in fair value below cost and more frequently when events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.

On October 17, 2023,Northern Swan Deutschland Holdings, Inc. (“Northern Swan”), a wholly-owned subsidiary of the Company entered into an agreement for sale of its remaining investments in the shares of Cansativa. The Company considered the sale price as fair value of the investment and recognized an impairment loss of $3,705 as the difference between fair value and carrying value of these investment at September 30, 2023. For more information, refer to Note 7 and Note 20.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

The following table provides a summary of changes in fair value of the Company’s level 3 investments for the nine months ended September 30, 2023:


	Level 3
Balance, December 31, 2022	$	5,679
Change in value due to foreign exchange gain	74
Balance, March 31, 2023	$	5,753

Change in value due to foreign exchange gain	24
Balance, June 30, 2023	$	5,777
Change in value due to foreign exchange loss	(176)
Impairment loss	(3,705)
Balance, September 30, 2023	$	1,896

During the nine months ended September 30, 2023, there were no transfers between fair value measurement levels.

The change in fair value of warrant liabilities related to private warrants during the nine months ended September 30, 2023, is as follows:


Private Placement Warrants:	Total Warrant Liability
Warrant liability at December 31, 2022	$	113
Change in fair value of warrant liability	44
Warrant liabilities at March 31, 2023	$	157
Change in fair value of warrant liability	11
Warrant liabilities at June 30, 2023	$	168
Change in fair value of warrant liability	(60)
Warrant liabilities at September 30, 2023	$	108

The Company determined the fair value of its private warrants using the Monte Carlo simulation model. The following assumptions were used to determine the fair value of the Private Warrants as of September 30, 2023 and December 31, 2022:


	As of
	September 30, 2023	December 31, 2022
Risk-free interest rate	4.98%	4.23%
Expected volatility	160%	105%
Share Price	$0.12	$0.31
Exercise Price	$11.50	$11.50
Expiration date	December 18, 2025	December 18, 2025

•The risk-free interest rate assumptions are based on U.S. dollar zero curve derived from swap rates at the valuation date, with a term to maturity matching the remaining term of warrants.

•The expected volatility assumptions are based on average of historical volatility based on comparable industry volatilities of public warrants.

•Exercise price and Share price at September 30, 2023 are adjusted post Reverse Share Split.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

5. INVENTORIES, NET

Inventories are comprised of the following items as of the periods presented:


	September 30, 2023		December 31, 2022
Raw materials	$	1,213	$	1,204
Work in progress – harvested cannabis and extracts	279		21
Finished goods – cannabis extracts	5,832		6,703
Finished goods – other	385		471
Total	$	7,709	$	8,399

During the three and nine months ended September 30, 2023 the Company recorded inventory provisions for approximately $264 and $591, respectively, to cost of sales to write-down obsolete inventories. During the three and nine months ended September 30, 2022, the Company recorded inventory provisions for approximately $555 and $1,103, respectively, to cost of sales to write-down obsolete inventory.

6. PREPAID, DEPOSITS AND OTHER RECEIVABLES

Prepaid and advances are comprised of the following items as of the periods presented:


	September 30, 2023		December 31, 2022
Prepaid and advances	$	765	$	650
Indirect tax receivables	1,080		2,007
Deposits	96		51
Total	$	1,941	$	2,708

Prepaid and advances represents amounts paid upfront to vendors for director and officer's insurance and advances for supplies.

7. INVESTMENTS

Cansativa

On December 21, 2018, the Company, through its subsidiary Northern Swan , entered into a seed investment agreement with the existing stockholders of Cansativa GmbH (“Cansativa”), a German limited liability company primarily focused on the import and sale of cannabis products for medical use and related supplements and nutraceuticals. Prior to the Company’s investment, Cansativa’s registered and fully paid-in share capital amounted to 26,318 common shares. Under the investment agreement, the Company has agreed with the existing stockholders to invest up to EUR 7,000 in Cansativa in three separate tranches of, respectively, EUR 1,000, EUR 3,000 and up to a further EUR 3,000. The first EUR 1,000 (specifically, EUR 999.92, approximately $1,075, or “Seed Financing Round”) was invested in Cansativa to subscribe for 3,096 newly issued preferred voting shares at EUR 322.97 per preferred share, and as cash contributions from the Company to Cansativa. The seed EUR 322.97 per share price was based on a fully diluted pre-money valuation for Cansativa of EUR 8,500, and the increase of Cansativa’s registered share capital by the 3,096 preferred shares in the Seed Financing Round provided the Company with 10.53% of the total equity ownership of Cansativa. The Company paid the seed investment subscription by, first, an initial nominal payment of EUR 3.1, (i.e., EUR 1.00 per share) upon signing the investment agreement to demonstrate the Company’s intent to invest, and the remainder of EUR 996.82 was settled in January 2019 to officially close the investment deal after certain closing conditions have been met by the existing stockholders and Cansativa. The Company accounted for its investment in Cansativa using the equity accounting method, due to the Company's significant influence, in accordance with ASC 323, Investments — Equity Method and Joint Ventures.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

The Company recorded its investment in Cansativa at the cost basis of an aggregated amount of EUR 999.92, approximately $1,075, which is comprised of EUR 3.10 for the initial nominal amount of the Seed Financing Round and EUR 996.82 for the remaining Seed Financing Round (i.e., Capital Reserve Payment), with no transaction costs.

In accordance with the seed investment agreement, in September 2019, the Company made an additional investment of approximately EUR 650, or approximately $722, for 2,138 shares in Cansativa, thereby increasing its equity ownership to 16.6% of the book value of Cansativa’s net assets of approximately EUR 1,233, and approximately EUR 1,122 of equity method goodwill as Cansativa was still in the process of getting the licenses and expanding its operations. As of September 30, 2020, the balance of Tranche 2 option expired un-exercised and as a result the Company recognized a loss on investment of approximately $370 in its Statement of Operations and Comprehensive Loss and the carrying value of the Tranche 2 option was reduced to nil.

In December 2020, Cansativa allocated shares of its common stock to a newly installed employee-stock ownership plan (“ESOP”). As a result of the ESOP installment, the Company’s equity ownership of Cansativa, on a fully-diluted basis, decreased from 16.59% to 15.80% of the book value of Cansativa’s net assets. Additionally, Cansativa raised additional capital through the issuance of Series A preferred stock (“Cansativa Series A Shares”) to a third-party investor at a per share price of EUR 543.31. As a result of the Series A Share issuance, the Company’s equity ownership of Cansativa, on a fully diluted basis, decreased from 15.80% to 14.22% of the book value of Cansativa’s net assets. The Company accounted for the transaction as a proportionate sale of ownership share and recognized a gain of approximately $211 in its consolidated statement of operations within loss on investments line. This change did not impact the equity method classification.

In April 2022, the Company sold 1,586 shares in Cansativa to an unrelated third-party for approximately EUR 2,300. Additionally Cansativa issued 10,184 series B and 992 ESOP shares. As a result, the Company's equity ownership of Cansativa, on a fully diluted basis, decreased from 14.22% to 7.6% of the book value of Cansativa's net assets. Furthermore, the Company relinquished the board seat, indicating that the Company's influence was no longer "significant", to which the equity method of accounting was applicable. The Company started to account for this investment under ASC 321, Investments – Equity Securities. The Company utilized the practical expedient under ASC 321 as the investment does not qualify for the practical expedient under ASC 820 and there is no readily determinable fair value for these privately held shares of Cansativa on a recurring basis. At the time of the sale, the Company compared the transaction value of the shares sold to the carrying value of shares sold and recognized a gain of $1,983. Immediately following the sale, the Company then remeasured its retained interest which resulted in an additional gain of $4,868. A total of $6,851 is recorded as gain on investment during the nine months period ended September 30, 2022.

On October 17, 2023, Northern Swan entered into an agreement to sell a total of 3,648 shares of Cansativa to Cansativa and EIP Entrepreneurial Investment GmbH, representing Northern Swan’s entire interest in Cansativa, for approximately EUR 1.8 million ($1.9 million). The Company compared the subsequent transaction value of the shares sold to the carrying value and the impairment loss of $3,705 was recorded in the Consolidated statement of Operations during the three and nine months ended September 30, 2023.

8. INTANGIBLE ASSETS, NET

As part of the Herbal Brand acquisition in 2019, the Company acquired finite-lived intangible assets with a gross value of approximately $7,091. During the three months ended September 30, 2023 and 2022 the Company recorded $167 and $191, respectively, of amortization related to its finite-lived intangible assets. During the nine months ended September 30, 2023 and 2022 the Company recorded $533 and $573, respectively, of amortization related to its finite-lived intangible assets.The following tables present details of the Company’s total intangible assets as of September 30, 2023 and December 31, 2022. The value of product formulation intangible asset is included in the value of Brand:

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)


	September 30, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		767		233		2.6
Customer list	650		574		76		0.6
Trade name	4,516		2,004		2,512		5.6
Total finite-lived intangible assets	$	7,091	$	4,270	$	2,821


	December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		669		331		3.0
Customer list	650		478		172		1.3
Trade name	4,516		1,665		2,851		6.3
Total finite-lived intangible assets	$	7,091	$	3,737	$	3,354

Indefinite-lived intangible assets:
Licenses	$	19,000	N/A		$	19,000
Impairment Charge	(19,000)		N/A		(19,000)
Total indefinite-lived intangible assets	—				—

Total intangible assets	$	7,091	$	3,737	$	3,354

Annual Impairment Testing

In accordance with ASC Topic 350, “Intangibles – Goodwill and Other,” the Company performs its annual impairment test as

of December 31 of each year. As part of the review, the Company has performed a qualitative assessment to determine whether indicators of impairment existed, along with considering, among other factors, the financial performance, industry conditions, as well as microeconomic developments. The Company also reviews intangibles for impairment whenever events or changes in circumstances indicate that the carrying value of its intangibles may not be recoverable. After the close of each interim quarter,

management assesses whether any indicators of impairment exist requiring the Company to perform an interim goodwill and other intangible assets impairment analysis.

Impairment Testing - Finite-Lived Intangibles

In conjunction with the 2022 annual impairment testing, the Company reviewed finite-lived intangible assets for impairment. In performing such review, the Company makes judgments about the recoverability of purchased finite lived intangible assets whenever events or changes in circumstances indicate that an impairment may exist. The Company recognizes an impairment if the carrying amount of the long-lived asset group exceeds the Company’s estimate of the asset group’s undiscounted future

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

cash flows. For the nine months ended September 30 2023, no impairment was recognized related to the carrying value of any of the Company's finite lived intangible assets. The Company will perform an impairment test at fiscal year ending December 31, 2023.

Impairment Testing - Indefinite-Lived Intangibles

In 2022, due to the continued decline in the Company’s share price and the projected revenues falling behind target, the Company performed an interim impairment assessment on its indefinite-lived intangible assets, consisting of cannabis related licenses for its Colombian operations. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including assumptions about revenue projections, regulations, operating margins, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods and discount rates. Utilizing a discounted cash flow model with a weighted average cost of capital (“WACC”) of 24%, the Company performed the assessment and recognized an impairment charge of $19,000 along with the related deferred tax liability write-off of $6,650 for the year ended December 31, 2022. As a result of this recognition in 2022, no indefinite-lived intangible assets exist as of September 30, 2023.

Amortization Expense

The following table reflects the estimated future amortization expense for each period presented for the Company’s finite-lived intangible assets as of September 30, 2023:


	Estimated Amortization Expense
2023	$	167
2024	585
2025	542
2026	482
2027	452
Thereafter	593
Total	$	2,821

9. PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net consisted of the following:


	September 30, 2023		December 31, 2022
Land	$	1,806	$	1,806
Building & warehouse	7,768		7,658
Laboratory equipment	6,496		6,416
Agricultural equipment	1,480		1,477
Computer equipment	1,433		1,397
Furniture & appliances	794		785
Construction in progress	106		240
Other	1,258		1,304
Property, plant and equipment, gross	21,141		21,083
Less: accumulated depreciation	(8,389)		(7,120)
Property, plant and equipment, net	$	12,752	$	13,963

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

10. DEBT


	September 30, 2023		December 31, 2022
Loans and borrowings, current portion	$	477	$	465
Loans and borrowings, non-current portion	859		1,065
Total debt	$	1,336	$	1,530

Portugal Debt

In January 2021, Clever Leaves Portugal Unipessoal LDA borrowed €1,000 ($1,213) (the "Portugal Debt"), from a local lender (the "Portugal Lender") under the terms of its credit line agreement. The Portugal Debt pays interest quarterly at a rate of Euribor plus 3.0 percentage points.

For the three months ended September 30, 2023 and 2022, the company recognized interest expense of approximately €11 ($12) and €7 ($7), respectively, and repaid principal of approximately €63 ($68) and €63 ($63), respectively, of the Portugal Debt in accordance with the terms of the loan agreement. For the nine months ended September 30, 2023 and 2022, the company recognized interest expense of approximately €31 ($33) and €22 ($24), respectively, and repaid principal of approximately €188 ($201) and €188 ($200), respectively, of the Portugal Debt in accordance with the terms of the loan agreement. As of September 30, 2023 and December 31, 2022, the outstanding principal balance of the Portugal Debt was €563 ($604) and €875 ($1,076), respectively.

Colombia Debt

Ecomedics S.A.S. has entered into loan agreements with multiple local lenders (collectively, the "Colombia Debt"), under which the Company borrowed approximately COP$5,305,800 ($1,295) of mainly working capital loans. The working capital loans are secured by mortgage of our farm land in Colombia as collateral. These loans bear interest at a range of 10.96% to 12.25% per annum denominated in Colombian pesos. The first payment of the principal and interest was repaid six months after receiving the loan. After the first payment, the principal and interest is repaid semi-annually.

For the three months ended September 30, 2023 and 2022, the Company recognized interest expense of approximately COP$53,145 ($21) and COP$7,809 ($2), respectively. For the nine months ended September 30, 2023 and 2022, the Company recognized interest expense of approximately COP$160,245 ($64) and COP$259,144 ($67) respectively, and repaid principal of approximately COP$222,978 ($53) and COP$875,864 ($213), respectively. For the period ended September 30, 2023, and December 31, 2022, the outstanding principal balance was approximately COP$2,967,844 ($732) and COP$3,471,576 ($725), respectively.

11. CAPITAL STOCK

Common Shares

As of September 30, 2023 and December 31, 2022, a total of 1,726,145 and 1,454,559 common shares were issued and outstanding, respectively. For more information, refer to Note 2. The increase in outstanding shares was primarily the result of shares issued under the ATM. See Equity Distribution Agreement disclosed below.

Reverse Share Split

On August 24, 2023, the Company effected a one-for-thirty Reverse Share Split of its common shares All share and per share information in these financial statements has been retroactively adjusted to reflect the Reverse Share Split. No fractional shares were issued in connection with the Reverse Share Split. Instead, each fractional share remaining after completion of the Reverse

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

Share Split that was less than half of a whole share was rounded down and canceled without consideration to the holders thereof and each fractional share that was at least half of a whole share was rounded up to one whole share.

As a result of the Reverse Share Split, at the Effective Time, the number of outstanding Shares was reduced from approximately 45.7 million to approximately 1.5 million.

The Reverse Share Split was, effected to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of at least $1.00 per share.

For the three months ended September 30, 2023, the Company issued and sold 201,912 shares on a post-Reverse Share Split basis pursuant to the ATM offering, for aggregate net proceeds of $824 which consisted of gross proceeds of $902 and $78 of equity issuance costs.

For the nine months ended September 30, 2023, the Company issued and sold 253,898 shares on a post-Reverse Share Split basis pursuant to the ATM offering, for aggregate net proceeds of $1,140 which consisted of gross proceeds of $1,340 and $200 of equity issuance costs.

Equity Distribution Agreement

On January 14, 2022, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC, as sales agent (the “Agent”). Under the terms of the Equity Distribution Agreement, the Company may issue and sell its common shares, without par value, having an aggregate offering price of up to $50,000 from time to time through the Agent. The issuance and sale of the common shares under the Equity Distribution Agreement have been made, and any such future sales will be made, pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-262183), which includes an “at-the-market” (“ATM”) offering prospectus supplement (the "Prospectus Supplement"), as amended from time to time.

Following the filing of the 2022 Form 10-K, we are subject to the limitations under General Instruction I.B.6. of Form S-3. and , we filed Amendment No. 3 to the Prospectus Supplement, to reflect the lower maximum offering amount based on the then aggregate market value of our outstanding common shares held by non-affiliates. If our public float increases such that we may sell additional amounts under the Equity Distribution Agreement and the Prospectus Supplement, we will file another amendment to the Prospectus Supplement prior to making additional sales.

Warrants

As of September 30, 2023, the Company had 12,877,361 of its public warrants classified as a component of equity and 4,900,000 of its private warrants recognized as liability. In connection with the Reverse Share Split, the warrants were adjusted in accordance with their terms such that each warrant entitles the holder to purchase 1/30 common share, at an exercise price of $345 per share. The warrants will expire on December 18, 2025, at 5:00 p.m., New York City time, or earlier upon redemption. The Company may redeem the outstanding public warrants at a price of $0.01 per warrant if the last reported sales price of the Company’s common shares equals or exceeds $540.00 per share (as adjusted for share splits, share capitalization, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the date on which the Company will send the notice of redemption to the warrant holders. The private warrants were issued in the same form as the public warrants, but they (i) are not redeemable by the Company and (ii) may be exercised for cash or on a cashless basis at the holder’s option, in either case as long as they are held by the initial purchasers or their permitted transferees (as defined in the warrant agreement). Once a private warrant is transferred to a holder other than an affiliate or permitted transferee, it is treated as a public warrant for all purposes. The terms of the warrants may be amended in a manner that may be adverse to holders with the approval of the holders of at least a majority 50.1% of the then outstanding warrants.

In accordance to ASC 815, certain provisions of private warrants that do not meet the criteria for equity treatment are recorded as liabilities with the offset to additional paid-in capital and are measured at fair value at inception and at each reporting period in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations and comprehensive loss in the period of change.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

As of September 30, 2023, the Company performed a valuation of the private warrants and as a result recorded a net loss on remeasurement for the three and nine months ended September 30, 2023, of approximately $60 and $5, respectively, in its statement of operations.

As of September 30, 2022, the Company performed a valuation of the private warrants and as a result recorded, in the statement of operations, a net gain on remeasurement for the three and nine months ended September 30, 2022 of approximately $196 and $2,009, respectively.

12. GENERAL AND ADMINISTRATION

The components of general and administrative expenses were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Salaries and benefits	$	2,263	$	2,781	$	7,464	$	9,719
Office and administration	736		1,096		2,168		3,169
Professional fees	667		495		2,933		2,893
Share based compensation	52		958		954		2,606
Rent	178		196		564		627
Other (a)	259		(84)		244		(149)
Total	$	4,155	$	5,442	$	14,327	$	18,865

(a) For the nine months ended September 30, 2023 and 2022, other general and administrative costs includes freight-out cost of approximately $464 and $454, respectively, related to costs of packaging, labelling, and courier services, respectively.

13. RESTRUCTURING EXPENSE

The Company has been reviewing, planning and implementing various strategic initiatives targeted principally at reducing costs, enhancing organizational efficiency and optimizing its business model. As part of this process, the Company recorded a restructuring charge related to asset write off, severance, and other related costs during the year 2022. For the nine months ended September 30, 2022, the Company recorded $3,761 of restructuring charge related to asset write off, severance, and other related costs. No such restructuring expense was charged during the nine months ended September 30, 2023.

Our restructuring charges are comprised primarily of costs related to asset abandonment, including future lease commitments, and employee termination costs related to headcount reductions.

14. SHARE-BASED COMPENSATION

Stock-Based Compensation Plans

The Company's 2018 Equity Incentive Plan, 2020 Equity Incentive Plan and Earnout Plan are described in the Company's 2022 Form 10-K.

In connection with the Reverse Share Split, at the Effective Time, the maximum number of Shares issuable under each of the Company’s 2020 Incentive Award Plan, as amended (the “Incentive Award Plan”), and the Company’s 2020 Earnout Award Plan (the “Earnout Plan” and together, the “Plans”) has been equitably adjusted to reflect the Reverse Share Split.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

The number of Shares underlying each award of restricted share units (whether vesting based on time or performance) issued under the Plans that were outstanding as of immediately prior to the Reverse Share Split has been ratably adjusted to reflect the Reverse Share Split.

Each award of restricted share units issued under the Earnout Award Plan that vested based on the achievement by the Company of certain threshold Share prices, outstanding as of immediately prior to the Reverse Share Split, has had its Share price targets ratably adjusted to reflect the Reverse Share Split.

The number of Shares underlying stock option awards issued under the Incentive Award Plan that were outstanding and unexercised as of immediately prior to the Reverse Share Split and the exercise price of such stock options has been ratably adjusted to reflect the Reverse Share Split.

Share-Based Compensation Expense

The following table summarizes the Company's share-based compensation expense for each of its awards, included in the Consolidated Statements of Operations for the three and nine months ended September 30, 2023.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Share-based compensation award type:
Stock Options	$	7	$	66	$	820	$	336
RSUs	45		892		134		2,270
Total Shared Based Compensation Expense	$	52	$	958	$	954	$	2,606

The Company recognized share-based compensation expense in general and administrative expense.

Stock Options

The following table is a summary of options activity for the Company’s equity incentive plans for the nine months ended September 30, 2023:


	Stock Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance as at December 31, 2022	13,619	$	233.46	2.56	$	—


Forfeited	(479)	$	336.36	—	—
Expired	(4,222)	$	320.87	—	—
Balance as of September 30, 2023	8,918	$	157.03	1.52	$	—
Vested and expected to vest as of September 30, 2023	8,576	$	151.33	1.56	$	—
Vested and exercisable as of September 30, 2023	7,731	$	123.73	1.04	$	—

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common shares for all stock options that had exercise prices lower than the fair value of the Company’s common shares.

The share-based compensation expense related to unvested stock options awards not yet recognized as of September 30, 2023 and December 31, 2022, was $166 and $392, respectively, which is expected to be recognized over a weighted average period

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

of 0.95 and 1.0 years respectively.

Restricted Share Units

Time-based Restricted Share Units

The fair value for time-based RSUs is based on the closing price of the Company’s common shares on the grant date.

The following table summarizes the changes in the Company’s time-based restricted share unit activity during the nine months ended September 30, 2023:


	Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested as of December 31, 2022	45,566	$	105.05
Granted	45,251	7.49
Vested	(18,108)	88.96
Canceled/forfeited	(5,602)	43.38
Non-vested as of September 30, 2023	67,107	$	48.75

Market-based Restricted Share Units

The Company has previously granted RSUs with both a market condition and a service condition (market-based RSUs) to the Company’s employees. No such market-based RSUs were granted during the nine months ended September 30, 2023. The market-based condition for these awards requires that (i) the Company’s common shares maintain a closing price equal to or greater than $12.50 for any 20 trading days within any consecutive 30 trading day period on or before December 18, 2022 (which condition was met on March 16, 2021) or (ii) the Company's common shares maintain a closing price equal to or greater than $15.00 for any 20 trading days within any consecutive 30 trading day period on or before December 18, 2024. Provided that the market-based condition is satisfied, and the respective employee remains employed by the Company, the market-based restricted share units will vest in four equal annual installments on the applicable vesting date.

The following table summarizes the changes in the Company’s market-based restricted share unit activity during the nine months ended September 30, 2023:


	Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested as of December 31, 2022	17,632	$	384.03
Granted	—	—
Vested	(15)	274.52
Expired	(71)	272.58
Forfeited	(3,874)	393.29
Non-vested as of September 30, 2023	13,672	$	382.11

15. REVENUE

The Company’s policy is to recognize revenue at an amount that reflects the consideration that the Company expects that it will be entitled to receive in exchange for transferring goods or services to its customers. The Company’s policy is to record revenue when control of the goods transfers to the customer. The Company evaluates the transfer of control through evidence of the customer’s receipt and acceptance, transfer of title, the Company’s right to payment for those products and the customer’s

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

ability to direct the use of those products upon receipt. Typically, the Company’s performance obligations are satisfied at a point in time, and revenue is recognized, either upon shipment or delivery of goods. In instances where control transfers upon customer acceptance, the Company estimates the time period it takes for the customer to take possession and the Company recognizes revenue based on such estimates. The transaction price is typically based on the amount billed to the customer and includes estimated variable consideration where applicable.

Disaggregation of Revenue

Refer to Note 16 Segment Reporting to our unaudited condensed consolidated interim financial statements for the period ended September 30, 2023 included in this Form 10-Q for disaggregation of revenue data.

Contract Balances

The timing of revenue recognition, billing and cash collections results in billed accounts receivable and deferred revenue primarily attributable to advanced customer payment, on the Consolidated Statements of Financial Position. Accounts receivables are recognized in the period in which the Company's right to the consideration is unconditional. The Company's contract liabilities consist of advance payment from a customer, which is classified on the Consolidated Statements of Financial Position as current and non-current deferred revenue.

As of September 30, 2023, the Company's deferred revenue, included in current and non-current liabilities was $437 and $nil, respectively.

As of December 31, 2022, the Company's deferred revenue, included in current and non-current liabilities was $1,072 and $nil, respectively.

16. SEGMENT REPORTING

Operating segments include components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (the Company’s Chief Executive Officer, “CEO”) in deciding how to allocate resources and in assessing the Company’s performance.

Operating segments for the Company are organized by product type and managed by segment managers who are responsible for the operating and financial results of each segment. Due to the similarities in the manufacturing and distribution processes for the Company’s products, much of the information provided in these consolidated financial statements and the footnotes to the consolidated financial statements, is similar to, or the same as, that information reviewed on a regular basis by the Company’s CEO.

The Company’s management evaluates segment profit/loss for each of the Company’s operating segments. The Company defines segment profit/loss as income from continuing operations before interest, taxes, depreciation, amortization, share-based compensation expense, gains/losses on foreign currency fluctuations, gains/losses on the early extinguishment of debt and miscellaneous expenses. Segment profit/loss also excludes the impact of certain items that are not directly attributable to the reportable segments’ underlying operating performance. Such items are shown below in the table reconciling segment profit/(loss) to consolidated income/(loss) from continuing operations before income taxes. The Company does not have any material inter-segment sales. Information about total assets by segment is not disclosed because such information is not reported to or used by the Company’s CEO. Segment intangible assets, net, are disclosed in Note 8.

As of September 30, 2023, the Company’s operations were organized in the following two reportable segments:

1.The Cannabinoid operating segment: comprised of the Company’s cultivation, extraction, manufacturing and commercialization of cannabinoid products. This operating segment is in the early stages of commercializing cannabinoid products internationally pursuant to applicable international and domestic legislation, regulations, and other permits. The Company’s principal customers and sales for its products are primarily outside of the U.S.

2.Non-Cannabinoid operating segment: comprised of the brands acquired as part of the Herbal Brands acquisition in April 2019. The segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, wellness products, detoxification products,

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

nutraceutical, and nutritional and dietary supplements. The Company’s principal customers for its Herbal Brands products include mass retailers, specialty and health retailer and distributors in the U.S.

The following table is a comparative summary of the Company’s net sales and segment profit by reportable segment for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022 (*)		2023		2022 (*)
Segment Net Sales:
Cannabinoid	$	1,442	$	613	$	4,537	$	3,166
Non-Cannabinoid	2,378		2,254		8,242		8,842
Total net sales	3,820		2,867		12,779		12,008

Segment Profit (Loss):
Cannabinoid	(2,225)		(2,732)		(6,237)		(11,144)
Non-Cannabinoid	316		95		1,594		1,109
Total segment loss	$	(1,909)	$	(2,637)	$	(4,643)	$	(10,035)

Reconciliation:
Total segment loss	(1,909)		(2,637)		(4,643)		(10,035)
Unallocated corporate expenses	(1,706)		(1,424)		(5,835)		(6,801)
Non-cash share-based compensation	(52)		(958)		(954)		(2,606)
Depreciation and amortization	290		(305)		750		(950)

Goodwill impairment	—		(19,000)		—		(19,000)
Loss from continuing operations before income taxes	$	(3,377)	$	(24,324)	$	(10,682)	$	(39,392)

Loss on debt extinguishment, net	—		—		—		2,263

Gain on remeasurement of warrant liability	(60)		(196)		(5)		(2,009)
Gain on investment	—		—		—		(6,851)
Impairment investment	3,705		—		3,705		—
Foreign exchange loss	275		669		297		1,144
Interest and amortization of debt issuance cost	5		(58)		23		2,696
Other (income) expense, net	(31)		102		(19)		111
Income (loss) before loss from equity investment	$	(7,271)	$	(24,841)	$	(14,683)	$	(36,746)

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

The following table disaggregates the Company’s revenue by channel for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Mass retail	$	2,618	$	1,570	$	8,133	$	6,065
Distributors	923		927		3,738		4,250
Specialty, health and other retail	107		282		361		1,234
E-commerce	172		88		547		459
Total	$	3,820	$	2,867	$	12,779	$	12,008

The following table represents the Company's revenues attributed to countries based on location of customer:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
United States	$	2,378	$	2,228	$	8,242	$	8,736
Israel	—		$	—	$	600	$	704
Australia	685		77		1,392		445
Brazil	507		249		1,778		1,169
Germany	59		275		68		722
Other	191		38		699		232
Total	$	3,820	$	2,867	$	12,779	$	12,008

Customers with an accounts receivable balance of 10% or greater of total accounts receivable and customers with net revenue of 10% or greater of total revenues are presented below for the periods indicated:

Percentage of Revenues

Percentage of Accounts Receivable

Three Months Ended September 30,

Nine Months Ended September 30,

September 30,

December 31,

2023

2022

2023

2022

2023

2022

Customer A (a)

10%

20%

12%

13%

18%

Customer B (b)

20%

13%

Customer C (b)

11%

Customer D (b)

15%

Customer E (b)

13%

15%

10%

Customer F (b)

16%

Customer G (b)

13%

* denotes less than 10%

(a) net sales attributed are reflected in the non-cannabinoid segments

(b) net sales attributed are reflected in the cannabinoid segments

During the three and nine months ended September 30, 2023 and 2022, the Company's net sales for the non-cannabinoid segment were in the U.S.; cannabinoid net sales were mostly outside of the U.S., primarily in Israel, Brazil and Australia.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

The following table disaggregates the Company’s long-lived assets, by segment for the periods presented:


	September 30, 2023		December 31, 2022
Long-lived assets
Cannabinoid	$	14,163	$	15,308
Non-Cannabinoid	89		155
Total	$	14,252	$	15,463

Long-lived assets consist of non-current assets other than goodwill; intangible assets, net; investments in unconsolidated subsidiaries and equity securities; and financial instruments.

17. NET INCOME (LOSS) PER SHARE

Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the year, without consideration for common share equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common share equivalents outstanding for the year determined using the treasury-stock method. For purposes of this calculation, common share warrants and stock options are considered to be common share equivalents and are only included in the calculation of diluted net income per share when their effect is dilutive.

The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Loss from continuing operations	$	(7,271)	$	(18,191)	$	(14,683)	(30,160)
Income (loss) from discontinued operations	$	2,133	$	(1,972)	$	1,869	(7,189)
Net loss - basic and diluted	$	(5,138)	$	(20,163)	$	(12,814)	$	(37,349)





Denominator:
Weighted-average common shares outstanding - basic and diluted	1,580,456		1,407,419		1,513,575		1,221,107

Net loss per common share - basic and diluted:
Loss from continuing operations	$	(4.60)	$	(12.93)	$	(9.70)	$	(24.70)
Income (loss) from discontinued operations	$	1.35	$	(1.41)	$	1.23	$	(5.90)

The Company's potentially dilutive securities, which include common stock, warrants, stock options, and unvested restricted stock have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

The Company excluded the following potential common shares, presented based on amounts outstanding as of September 30, 2023 and September 30, 2022, from the computation of diluted net loss per share attributable to common shareholders because including them would have had an anti-dilutive effect:



	September 30, 2023	September 30, 2022
		(a)
SAMA earnout shares	19,007	19,007
Stock options	8,918	14,530
Unvested restricted share units	80,779	77,128
Total	108,704	110,665
Common Stock Warrants (b)	17,777,361	17,840,951

(a) Prior year numbers are adjusted for the Reverse Share Split.

(b) No change in number of warrants due to the Reverse Share Split. In connection with the Reverse Share Split, the warrants were adjusted in accordance with their terms such that each warrant entitles the holder to purchase 1/30 common share at an exercise price of $345 per share.

18. LEASES

On January 1, 2022, we adopted the accounting standard ASC 842, Leases, using the modified retrospective method. We elected this adoption date as our date of initial application. As a result, we have not updated financial information related to, nor have we provided disclosures required under ASC 842 for, periods prior to January 1, 2022. The primary changes to our policies relate to recognizing most leases on our statement of financial position as liabilities with corresponding right-of-use ("ROU") assets.

The Company has entered into agreements under which we lease various real estate spaces in North America, Europe and Latin America, under non-cancellable leases that expire on various dates through calendar year 2029. Some of our leases include options to extend the term of such leases for a period from 12 months to 60 months, and/or have options to early terminate the lease. Some of our leases require us to pay certain operating expenses in addition to base rent, such as taxes, insurance and maintenance costs.

As the Company’s leases do not typically provide an implicit rate, the Company utilizes the appropriate incremental borrowing rate, determined as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term and in a similar economic environment.

Practical Expedients

The modified retrospective approach included a package of optional practical expedients that we elected to apply. Among other things, these expedients permitted us not to reassess prior conclusions regarding lease identification, lease classification and initial direct costs under ASC 842. The Company does not separate lease and non-lease components in determining ROU assets or lease liabilities for real estate leases. Additionally, the Company does not recognize ROU assets or lease liabilities for leases with original terms or renewals of one year or less.

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)


	Financial Statement Classification	Three Months Ended September 30, 2023		Nine Months Ended September 30, 2023
Operating lease costs:
Fixed lease costs	Operating expenses	$	171	$	530
Total lease costs		$	171	$	530

The table above includes amounts relating to the Company's lease costs, which includes net costs recognized in our operating expenses during the period, including amounts capitalized as part of the costs of Inventory, in accordance with ASC 330. Variable lease costs primarily include maintenance, utilities and operating expenses that are incremental to the fixed base rent payments and are excluded from the calculation of operating lease liabilities and ROU assets. For the three and nine months ended September 30, 2023, cash paid for amounts associated with our operating lease liabilities was approximately $202 and $621, respectively, For the three and nine months ended September 30, 2022, cash paid for amounts associated with our operating lease liabilities were approximately $457 and $1,354, respectively, which were classified as operating activities in the consolidated statement of cash flows

The following table shows our undiscounted future fixed payment obligations under our recognized operating leases and a reconciliation to the operating lease liabilities as of September 30, 2023:


Leases and a reconciliation to the operating lease liabilities as of September 30, 2023
Remainder of Year 2023	$	183
2024	370
2025	107
2026	114
2027	113
Thereafter	84
Total future fixed operating lease payments	$	971

Less: Imputed interest	$	93
Total operating lease liabilities	$	878

Weighted-average remaining lease term - operating leases	2.89
Weighted-average discount rate - operating leases	8.0		%

Table of Contents

CLEVER LEAVES HOLDINGS INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(Amounts in thousands of U.S. dollars, except share and per share amounts and where otherwise noted)

19. DISCONTINUED OPERATIONS

As part of the restructuring activities, the Company conducted a comprehensive review of its production capacity for cannabis extracts. This evaluation led to the decision to scale back on certain extraction capacity and related assets, resulting in asset write-off charges. The Company also approved the shutdown of its cultivation activities in Portugal to preserve cash and improve operating margins. The Company has completed the cessation of its Portuguese flower cultivation, post-harvest processes, and manufacturing activities. Subsequently, the post harvest facility has been sold and preparations are currently underway for the sale of the farm land with the objective of concluding the sale by March 31, 2024.

The company determined that shutdown of Portugal operations met the criteria to be classified as a discontinued operation, and, as a result, its historical financial results are reflected in the Company's financial statements as a discontinued operation and, assets and liabilities were classified as assets and liabilities held for sale.

To provide transparency and facilitate comparison, the table below presents the major line items constituting the pretax profit or loss of the discontinued operations for the three and nine months ended September 30, 2023, and the three and nine months ended September 30, 2022:


		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Revenue, net		$	—	$	438	$	551	$	1,178



Cost of sales		—		(1,456)		—		(3,929)
Gross profit (loss)		—		(1,018)		551		(2,751)
Expenses
General and administrative		584		645		1,430		3,496
Restructuring expenses		—				—		30
Depreciation and amortization		—		203		—		613
Total expenses		584		848		1,430		4,139

Loss from operations		(584)		(1,866)		(879)		(6,890)

Interest (income) expense		14		7		33		24
Gain on sale of assets	—	(2,778)		—		(2,825)
Foreign exchange loss		48		99		44		275
Other income, net		(1)		—		—		—

Net gain (loss)		$	2,133	$	(1,972)	$	1,869	$	(7,189)

Table of Contents

CLEVER LEAVES INTERNATIONAL INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except where otherwise noted and share and per share amounts)

20. COMMITMENT AND CONTINGENCIES

On July 1, 2023, an asset purchase agreement (the “APA”) was entered into by and among (the Company) as guarantor, Clever Leaves Portugal Unipessoal, Lda. (the “Seller” or “Clever Leaves Portugal”), a wholly-owned subsidiary of the Company, and Terra Verde, Lda. (the “Purchaser”), a wholly-owned subsidiary of Curaleaf International, part of Curaleaf Holdings, Inc. Pursuant to the APA, the Purchaser agreed to acquire, and the Seller agreed to sell, certain laboratory and processing equipment for the production of cannabinoid products, as well as informational rights to policies and procedures for the production and manufacture of such cannabinoids that the Seller used in its EU-GMP certified cannabis processing facility in Setubal, Portugal. Under the terms of the APA, the Company has provided a guarantee in case of malfunctioning of the equipment for a period of 12 months expiring July 2024. The total amount of the guarantee will not exceed, in any circumstances, €500 and undertakes the obligation of principal payor renouncing to the benefit of prior foreclosure of the Seller’s assets. The Company considers the probability of requiring payment under the guarantee to be remote. Hence, no liabilities or expenses are recorded in the financial statements.

21. SUBSEQUENT EVENTS

Agreement to sell Investment in Cansativa

On October 17, 2023, Northern Swan, a wholly-owned subsidiary of (the Company), entered into the First Share Purchase and Transfer Agreement (the “SPA”) by and among Northern Swan, as seller, and Cansativa GmbH (“Cansativa”) and EIP Entrepreneurial Investment GmbH (“EIP”), as buyers. Pursuant to the SPA, Northern Swan agreed to sell a total of 3,648 shares of Cansativa, representing its entire interest in Cansativa, of which 3,582 shares were purchased by Cansativa and 66 shares were purchased by EIP, for a total purchase price of approximately €1.8 million ($1.9 million). The Company received the funds in November, 2023.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Amounts in thousands of U.S. dollars, except as otherwise noted.

Our Company

We are a multi-national operator in the botanical cannabinoid and nutraceutical industries, with operations and investments in Colombia, Germany, the United States, and Canada We are working to develop one of the industry’s leading, low-cost global supply chains with the goal of providing high quality, pharmaceutical grade cannabis and wellness products to customers and patients at competitive prices produced in a sustainable and environmentally friendly manner. Our customers consist of retail distributors and pharmaceutical and cannabis companies, and pharmacies.

We have invested in ecologically sustainable, large-scale, cultivation and processing, as the cornerstone of our medical cannabinoid business, and we seek to continue to develop strategic distribution channels and brands.

We currently own approximately 1.8 million square feet of greenhouse cultivation capacity in Colombia. In addition, our pharmaceutical-grade extraction facility is capable of processing 108,000 kilograms of dry flower per year.

In July 2020, we became one of a small number of vertically integrated cannabis companies in the world to receive European Union Good Manufacturing Practices (“EU GMP”) certification for our Colombian operations. We believe this certification will provide us with one of the largest quality-certified licensed capacities for cannabis cultivation and cannabinoid extraction globally, while our strategically located operations allow us to produce our products at a fraction of the average cost of production incurred by our peers in Canada and the United States.

In addition to the cannabinoid business, we are also engaged in the non-cannabinoid business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing nutraceutical and other natural remedies, and wellness products to more than 20,000 retail locations across the United States, through our wholly owned subsidiary Herbal Brands, Inc. Herbal Brands has an Arizona based GMP-compliant, FDA registered facility and is a national distributor of nutraceutical products. Herbal Brands’ nationwide customer base provides a platform we intend to leverage for greater potential cannabinoid distribution in the future, should U.S. federal laws change and regulations permit.

Our business model is focused on partnering with leading and emerging cannabis and pharmaceutical businesses by providing them with lower cost product, variable cost structures, reliable supply throughout the year, and accelerated speed to market. We believe this is achievable due to our production locations, capacity, product registrations and various product certifications.

We manage our business in two segments: the Cannabinoid and Non-Cannabinoid segments.

1. The Cannabinoid operating segment is comprised of the Company’s cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products. This operating segment is in the early stages of commercializing cannabinoid products internationally subject to applicable international and state laws and regulations. Our customers and sales for our cannabinoid segment products are mostly outside of the U.S.

2. The Non-Cannabinoid operating segment is comprised of the brands and manufacturing assets acquired as part of our acquisition of Herbal Brands. The segment is engaged in the business of formulating, manufacturing, marketing, selling, distributing, and otherwise commercializing wellness products and nutraceutical, excluding cannabinoid products. Our principal customers for the Herbal Brands products include specialty and health retailers, mass retailers and specialty and health stores in the United States.

Table of Contents

Factors Impacting our Business

We believe that our future success will primarily depend on the following factors:

Globalization of the industry. Due to our multi-national operator model focused on geographic diversification, which distinguishes us from many of our competitors and allows us to scale our production in low-cost regions of the world, our goal is to capitalize in markets where the medical cannabis and hemp industry offers a reasonably regulated and free flow of goods across national boundaries. While certain countries, such as Canada, have historically not welcomed imported cannabis or hemp products for commercial purposes, other countries, such as Germany and Brazil, depend primarily on imports.

Global medical market expansion. Medical cannabis is now authorized at the national or federal level in over 41 countries, and more than half of these countries have legalized or introduced significant reforms to their cannabis-use laws to broaden the scope of permitted medical uses beyond the original parameters. Over the past three years, we have established regional operations in Colombia, Germany, the United States and Canada, and we have invested significant resources in personnel and partnerships to build the foundation for new export channels. The Company also owned agricultural and post-harvest facilities in Portugal which have since been wound down as a result of a restructuring initiative that was undertaken by management during December 2022.

Product development and innovation. Because of the rapid evolution of the cannabis industry, the disparate regulations across different geographies, and the time required to develop and validate pharmaceutical-grade products, the pace at which we can expand our portfolio of products and formulations will impact market acceptance for our products. To increase our output while maintaining or reducing unit costs, we may need to enhance our cultivation, extraction, and other processing methods. We believe our focus on the production of proprietary and exclusive products or formulations that comply with stringent regulations, or that result in enhanced benefits for patients or consumers, could create advantages in various markets.

Regulatory expertise and adaptation. As more markets welcome the importation of cannabis or hemp products for commercial purposes, this will require navigating and complying with the strict and evolving cannabis regulations across the different geographies. We have built a global regulatory team that is experienced in developing good relationships with regulatory agencies and governments that govern and shape the cannabis industry in their respective jurisdictions. Key expertise includes complying with and securing quotas, product approvals, export permits, import permits and other geographic specific licenses.

Strategically expanding productive capacity and manufacturing capabilities. It is beneficial to have low operating costs and to control the production process to generate consistency and quality on a large scale. As we seek to expand into new markets and grow our presence in existing markets, we will need significant investments in cultivation and processing, which will necessitate additional capital. We also aim to increase productive capacity through innovation in cultivation or processing methods, improving yields and output levels of our existing assets. While we believe our core cultivation and extraction operations in Colombia are adequately sized for our current business operations, we will need to expand our operations in Colombia and invest in advanced processing or finished good manufacturing capabilities to match any growth in Cannabis sales and expansion to local products.

Key Operating Metrics

We use the following key operating metrics to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance and make strategic decisions. Other companies, including companies in our industry, may calculate key operating metrics with similar names differently, which may reduce their usefulness as comparative measures.

Table of Contents

The following table presents select operational and financial information of the Cannabinoid segment for the three and nine months ended September 30, 2023 and 2022:



	Three months ended September 30,
Operational information:	2023		2022(*)		Change
(In $000s, except kilogram and per gram data)
Kilograms (dry flower) harvested (a) (d)	1,210		1,211		(1)		—	%
Costs to produce (b)	$	909	$	631	$	278	44	%
Costs to produce per gram	$	0.75	$	0.52	$	0.23	(25)	%

Selected financial information:
Revenue	$	1,442	$	621	$	821	132	%
Kilograms sold (c)	4,733		577		4,156		720	%
Revenue per gram sold	$	0.30	$	1.08	$	(0.77)	(72)	%



	Nine Months Ended September 30,
Operational information:	2023		2022(*)		Change
(In $000s, except kilogram and per gram data)
Kilograms (dry flower) harvested (a)	3,060		7,976		(4,916)		(62)	%
Costs to produce (b)	$	2,624	$	2,313	$	311	13	%
Costs to produce per gram	$	0.86	$	0.29	$	0.57	197	%

Selected financial information:
Revenue	$	4,537	$	3,263	$	1,274	39	%
Kilograms sold (c)	14,199		6,259		7,940		127	%
Revenue per gram sold	$	0.32	$	0.52	$	(0.20)	(38)	%

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

(a)Kilograms (dry flower) harvested - represents the weight of dried plants post-harvest both for sale and for research and development purposes. This operating metric is used to measure the productivity of our farms.

(b)Costs to produce - includes costs associated with cultivation, extraction, depreciation, quality assurance and supply chain related to kilograms (dry flower) harvested.

(c)Kilograms sold - represents the amount in kilograms of product sold in dry plant equivalents. Extract is converted to dry plant equivalent for purposes of this metric.

During the three months ended September 30, 2023 and 2022 we sold 4,733 and 577 kilograms, respectively, of dry flower equivalent supporting ongoing demand strength for our cannabinoid extracts and continued refining of Colombian flower. For the three months ended September 30, 2023, our Cannabinoid segment sales were primarily in Australia, and Brazil.

During the nine months ended September 30, 2023 and 2022 we sold 14,199 and 6,259 kilograms, respectively, of dry flower equivalent. For the nine months ended September 30, 2023, the increase in cannabinoid revenues was primarily driven by ongoing sales strength for the Company’s extract products, particularly in Brazil, Australia, and Israel.

We harvested 1,210 kilograms of cannabinoids in the three months ended September 30, 2023, as compared to 1211 kilograms in the three months ended September 30, 2022. The harvesting remained constant as compared to the prior period. The Company has continued to add new CBD hemp crops to its harvest cycle to replenish inventory for previously sold extract products, while mainly focusing Colombian harvests on growing THC flower for export.

Table of Contents

We harvested 3,060 kilograms of cannabinoids in the nine months ended September 30, 2023, as compared to 7,976 kilograms in the nine months ended September 30, 2022. The decrease was primarily attributable to a decrease in our production capacity at our Colombia facility.

Costs to produce were approximately $0.75 per gram of dry flower equivalent for the three months ended September 30, 2023, as compared to $0.52 per gram of dry flower equivalent for the three months ended September 30, 2022. The increase is attributable to the Company's ongoing extraction and processing costs on existing inventory, along with costs associated with ramping Colombian flower exports.

Costs to produce were approximately $0.86 per gram of dry flower equivalent for the nine months ended September 30, 2023, as compared to $0.29 per gram of dry flower equivalent for the nine months ended September 30, 2022. The increase is attributable to the Company's significantly reduced agricultural output for the first nine months of 2023 and changes in the cultivation techniques to improve the quality and properties of the flower as well as meet more stringent market and regulatory requirements, along with ongoing extraction and processing costs at its Colombian operations.

Recent Developments

Reverse Share Split

On August 24, 2023, the Company effected a one-for-thirty Reverse Share Split of its common shares. All share and per share information in these financial statements has been retroactively adjusted to reflect the Reverse Share Split. No fractional shares were issued in connection with the Reverse Share Split. Instead, each fractional share remaining after completion of the Reverse Share Split that was less than half of a whole share was rounded down and canceled without consideration to the holders thereof and each fractional share that was at least half of a whole share was rounded up to one whole share.

As a result of the Reverse Share Split, at the Effective Time, the number of outstanding Shares was reduced from approximately 45.7 million to approximately 1.5 million.

The Reverse Share Split was effected to, regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company, to maintain a minimum bid price of at least $1.00 per share.

Warrants

As of September 30, 2023, the Company had 12,877,361 of its public warrants classified as a component of equity and 4,900,000 of its private warrants recognized as liability. In connection with the Reverse Share Split, the warrants were adjusted in accordance with their terms such that each warrant entitles the holder to purchase 1/30 common share at an exercise price of $345 per share. The warrants expire on December 18, 2025, at 5:00 p.m., New York City time, or earlier upon redemption. The Company may redeem the outstanding public warrants at a price of $0.01 per warrant if the last reported sales price of the Company’s common shares equals or exceeds $540 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the date on which the Company will send the notice of redemption to the warrant holders. The private warrants were issued in the same form as the public warrants, but they (i) are not redeemable by the Company and (ii) may be exercised for cash or on a cashless basis at the holder’s option, in either case as long as they are held by the initial purchasers or their permitted transferees (as defined in the warrant agreement). Once a private warrant is transferred to a holder other than an affiliate or permitted transferee, it is treated as a public warrant for all purposes. The terms of the warrants may be amended in a manner that may be adverse to holders with the approval of the holders of at least a majority 50.1% of the then outstanding warrants.

Table of Contents

Equity Distribution Agreement

On January 14, 2022, we entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC, as sales agent (the “Agent”). Under the terms of the Equity Distribution Agreement, we may issue and sell our common shares, without par value, having an aggregate offering price of up to $50,000 from time to time through the Agent. The issuance and sale of the common shares under the Equity Distribution Agreement have been made, and any such future sales will be made, pursuant to our effective registration statement on Form S-3 (File No. 333-262183), which includes an “at-the-market” (“ATM”) offering prospectus supplement (the “Prospectus Supplement”), as amended from time to time.

Following the filing of the 2022 Form 10-K, we are subject to the limitations under General Instruction I.B.6. of Form S-3and we filed Amendment No. 3 to the Prospectus Supplement, to reflect the lower maximum offering amount based on the then aggregate market value of our outstanding common shares held by non-affiliates. If our public float increases such that we may sell additional amounts under the Equity Distribution Agreement and the Prospectus Supplement, we will file another amendment to the Prospectus Supplement prior to making additional sales.

For the three months ended September 30, 2023, the Company issued and sold after the Reverse Share Split 201,912 shares pursuant to the ATM offering, for aggregate net proceeds of $824 which consisted of gross proceeds of $902 and $78 of equity issuance costs.

For the nine months ended September 30, 2023, the Company issued and sold after the Reverse Share Split 253,898 shares pursuant to the ATM offering, for aggregate net proceeds of $1,140 which consisted of gross proceeds of $1,340 and $200 of equity issuance costs.

Components of Results of Operations

Revenue — in our Cannabinoid segment, revenue is primarily comprised of sales of our cannabis products, which currently include cannabidiol isolate, full spectrum and standardized extracts as well as dry smokable flowers. In our Non-Cannabinoid segment, revenue is primarily composed of sales of our nutraceutical products to our retail customers. As we continue to grow our cannabinoid sales operations, our main revenues are derived from our Herbal Brands business.

Cost of Sales — in our Cannabinoid segment, cost of sales is primarily composed of pre-harvest, post-harvest and shipment and fulfillment costs. Pre-harvest costs include labor and direct materials to grow cannabis, which includes water, electricity, nutrients, integrated pest management, growing supplies and allocated overhead. Post-harvest costs include costs associated with drying, trimming, blending, extraction, purification, quality testing and allocated overhead. Shipment and fulfillment costs include the costs of packaging, labelling, courier services and allocated overhead. Total cost of sales also includes cost of sales associated with accessories and inventory adjustments. In our Non-Cannabinoid segment, cost of sales primarily includes raw materials, labor, and attributable overhead, as well as packaging labelling and fulfillment costs.

Operating Expenses — We classify our operating expenses as general and administrative, sales and marketing, and research and development expenses.

•General and administrative expenses include salary and benefit expenses for employees, other than in sales and marketing and research and development, including share-based compensation, costs of legal expenses, professional services, general liability insurance, rent and other office and general expenses.

•Sales and marketing expenses consist primarily of services engaged in marketing and promotion of our products and costs associated with initiatives and development programs and salary and benefit expenses for certain employees.

•Research and development expenses primarily consist of salary and benefit expenses for employees engaged in research and development activities, as well as other general costs associated with R&D activities.

Results of Operations

Table of Contents

Three and nine months ended September 30, 2023 compared to three and nine months ended September 30, 2022

Consolidated Statements of Operations

(In thousands of U.S. dollars)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022 (*)		2023		2022 (*)
Revenue, net	$	3,820	$	2,867	$	12,779	$	12,008
Cost of sales:
Cost of sales	(1,614)		(1,013)		(5,286)		(4,532)
Inventory write-down	(264)		(555)		(591)		(1,103)
Cost of sales	(1,878)		(1,568)		(5,877)		(5,635)
Gross Profit	1,942		1,299		6,902		6,373

Expenses
General and administrative expenses	4,155		5,442		14,327		18,865
Sales and marketing expenses	582		615		1,600		2,075
Research and development	292		343		907		1,114
Restructuring expenses	—		(82)		—		3,761

Goodwill impairment	—		19,000		—		19,000
Depreciation and amortization expenses	290		305		750		950
Total expenses	5,319		25,623		17,584		45,765

Loss from operations	(3,377)		(24,324)		(10,682)		(39,392)

Other Expense (Income), net
Interest and amortization of debt issuance cost	5		(58)		23		2,696
Gain on remeasurement of warrant liability	(60)		(196)		(5)		(2,009)
Gain on investment	—		—		—		(6,851)
Loss on debt extinguishment, net	—		—		—		2,263

Impairment investment	3,705		—		3,705		—
Foreign exchange loss	275		669		297		1,144
Other (income) expense, net	(31)		102		(19)		111
Total other expenses (income), net	3,894		517		4,001		(2,646)

Loss before income taxes and equity investment loss	$	(7,271)	$	(24,841)	$	(14,683)	$	(36,746)
Deferred income tax (recovery)	—		(6,650)		—		(6,650)
Equity investments share of loss			—		—		64
Net income (loss)	$	(7,271)	$	(18,191)	$	(14,683)	(30,160)

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

Revenue by Channel

Table of Contents

(In thousands of U.S. dollars)

The following table provides our revenue by channel for the three and nine months ended September 30, 2023 and 2022.


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Mass retail	$	2,618	$	1,570	$	8,133	$	6,065
Distributors	923		927		3,738		4,250
Specialty, health and other retail	107		282		361		1,234
E-commerce	172		88		547		459
Total	$	3,820	$	2,867	$	12,779	$	12,008

Revenue

Net revenue increased to $3,820 for the three months ended September 30, 2023, as compared to $2,867 for the three months ended September 30, 2022. The increase was driven by an increase in cannabinoid segment revenues compared to the same period in 2022, and marginal increase in revenues in the non-cannabinoid segment. The increase in cannabinoid segment revenues was primarily driven by ongoing sales strength for the Company’s extract products, particularly in Brazil and Australia. The increase in non-cannabinoid revenues was due to improved demand in the segment’s mass retail channel during the quarter

Net revenue increased to $12,779 for the nine months ended September 30, 2023, as compared to $12,008 for the nine months ended September 30, 2022. . The increase was driven by an increase in the cannabinoid segment partially offsetting a decrease in the non-cannabinoid segment. The increase in net revenue was driven by an increase cannabinoid segment revenues due to ongoing sales strength for the Company’s extract products, particularly in Brazil, Australia, and Israel. The decrease in non-cannabinoid revenues due to continued demand headwinds in the segment’s specialty channel, resulted in lower inventory orders during the nine months ended September 30, 2023.

Cost of sales

Cost of sales increased to $1,878 for the three months ended September 30, 2023, as compared to $1,568 for the three months ended September 30, 2022. Approximately 68% of the increase was due to higher sales volumes and approximately 32% due to customer and product mix differences compared to the year ago period.

Cost of sales increased to $5,877 for the nine months ended September 30, 2023, as compared to $5,635 for the nine months ended September 30, 2022. The increase was primarily due to an increase in inventory provision and inventory write-down related to aged, obsolete or unusable inventory, during the nine months ended September 30, 2023 as compared to the comparable period last year

Operating expenses

(In thousands of U.S. dollars)

Table of Contents



	Three months ended September 30,
	2023			2022			Change
General and administrative expenses	$	4,155		$	5,442		$	(1,287)	(24)	%
Sales and marketing expenses	582			615			(33)		(5)	%
Research and development	292			343			(51)		(15)	%
Restructuring expenses	—			(82)			$	82	N/A
Goodwill impairment	—			19,000			(19,000)		N/M
Depreciation and amortization expenses	290			305			(15)		(5)	%
Total operating expenses	$	5,319		$	25,623

(As a percentage of revenue)
General and administrative expenses	109		%	190		%
Sales and marketing expenses	15		%	21		%
Research and development	8		%	12		%


Goodwill impairment	—		%	N/M
Depreciation and amortization expenses	8		%	11		%
Total operating expenses	139		%	N/M

N/M: Not a meaningful percentage



	Nine Months Ended September 30,
	2023			2022			Change
General and administrative expenses	$	14,327		$	18,865		$	(4,538)	(24)	%
Sales and marketing expenses	1,600			2,075			(475)		(23)	%
Research and development	907			1,114			(207)		(19)	%
Restructuring expenses	—			3,761			(3,761)		(100)	%

Goodwill impairment	—			19,000			(19,000)		(100)	%
Depreciation and amortization expenses	750			950			(200)		(21)	%
Total operating expenses	$	17,584		$	45,765

(As a percentage of revenue)
General and administrative expenses	112		%	157		%
Sales and marketing expenses	13		%	17		%
Research and development	7		%	9		%
Restructuring expenses	—		%	31		%

Goodwill impairment	—		%	158		%
Depreciation and amortization expenses	6		%	8		%
Total operating expenses	138		%	381		%

N/M: Not a meaningful percentage

Three months ended September 30, 2023 compared to three months ended September 30, 2022

General and administrative. General and administrative expenses decreased to $4,155 for the three months ended September 30, 2023, as compared to $5,442 for the three months ended September 30, 2022, primarily due to reduced share-based compensation and payroll expenses, reflecting the continued benefits of the cost cutting measures, and restructuring initiatives

Table of Contents

the Company previously implemented.

Sales and marketing. Sales and marketing expenses decreased to $582 for the three months ended September 30, 2023, as compared to $615 for the three months ended September 30, 2022. The decrease in spending was due to the cost-cutting measures related to our Non-Cannabinoid segment primarily for Herbal Brands.

Research and development. Research and development expenses decreased to $292 for the three months ended September 30, 2023 as compared to $343 for the three months ended September 30, 2022. The decrease is primarily due to the decrease in research and development activities related to our cannabinoid products development and also due to decrease in sample and test consumption.

Restructuring. There was a reversal of restructuring expense of $82 for the three months ended September 30, 2023 which was previously charged in first nine months ended September 30, 2023. There was no restructuring expense or reversal during the three month ended September 30, 2022.

Goodwill impairment: No goodwill impairment was charged for the three months ended September 30, 2023 as compared to $19,000 during the three months ended September 30, 2022 as the goodwill was fully written off during the year 2022.

Depreciation and amortization. Depreciation and amortization expenses decreased to $290 for the three months ended September 30, 2023, from $305 for the three months ended September 30, 2022. The decrease is mainly due to revised estimated useful life of certain fixed assets as mentioned in Note 3 to the financial statements.

Nine Months Ended September 30, 2023 compared to nine months ended September 30, 2022

General and administrative. General and administrative expenses decreased to $14,327 for the nine months ended September 30, 2023, as compared to $18,865 for the nine months ended September 30, 2022, primarily due to reduced share-based compensation and payroll expenses, reflecting the continued benefits of the cost cutting measures, and restructuring initiatives the Company previously implemented.

Sales and marketing. Sales and marketing expenses decreased to $1,600 for the nine months ended September 30, 2023, as compared to $2,075 for the nine months ended September 30, 2022. The decrease in spending was due to the cost-cutting measures related to Non-Cannabinoid segment primarily for Herbal Brands.

Research and development. Research and development expenses decreased to $907 for the nine months ended September 30, 2023 as compared to $1,114 for the nine months ended September 30, 2022. The decrease is primarily due to the decrease in research and development activities related to our cannabinoid products development.

Restructuring. We recorded a restructuring charge of $3,761 related to asset write off, severances, and other related costs for the nine months ended September 30, 2022. No such restructuring expense was charged during the nine months ended September 30, 2023.

Goodwill impairment: No goodwill impairment was charged for the nine months ended September 30, 2023 as compared to $19000 during the nine months ended September 30, 2022 as the goodwill was fully written off during the year 2022.

Depreciation and amortization. Depreciation and amortization expenses decreased to $750 for the nine months ended September 30, 2023, from $950 for the nine months ended September 30, 2022. The decrease is mainly due to revised estimated useful life of certain fixed assets as mentioned in Note 3 to the financial statements.

Table of Contents

Non-operating income and expenses

(In thousands of U.S. dollars)



	Three months ended September 30,
	2023		2022 (*)		Change
Interest and amortization of debt issuance cost	$	5	$	(58)	$	63	(109)	%
Gain on remeasurement of warrant liability	(60)		(196)		136		(69)	%



Investment impairment	3,705		—		3,705		N/M
Foreign exchange loss	275		669		(394)		(59)	%
Other expense (income), net	(31)		102		(133)		(130)	%
Total	3,894		$	517	$	3,377	N/M



	Nine Months Ended September 30,
	2023		2022 (*)		Change
Interest and amortization of debt issuance cost	$	23	$	2,696	$	(2,673)	(99)	%
Gain on remeasurement of warrant liability	(5)		(2,009)		2,004		(100)	%
Gain on investment	—		(6,851)		6,851		(100)	%
Loss on debt extinguishment, net	—		2,263		(2,263)		(100)	%

Investment impairment	3,705		—		3,705		N/M
Foreign exchange loss	297		1,144		(847)		(74)	%
Other expense (income), net	(19)		111		(130)		(117)	%
Total	4,001		$	(2,646)	$	6,647	N/M

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

Three months ended September 30, 2023 compared to three months ended September 30, 2022

Interest and amortization of debt issuance cost, net. For the three months ended September 30, 2023 interest expense increased to $5, as compared to interest income of $58 for the three months ended September 30, 2022. The interest expense the three month ended September 30, 2023 is related to the increased interest rates for the Portugal and Colombia debt. The Company had interest income, net for the amount of $58 from the cash held in its savings accounts in the three months ended September 30, 2022..

Gain on remeasurement of warrant liability. Gain on remeasurement of warrant liability was $60 for the three months ended September 30, 2023, as compared to a gain of $196 for the three months ended September 30, 2022. The gains are directly attributable to the remeasurement of the warrant liability as of September 30, 2023 and September 30, 2022, respectively, due to the change in the underlying value related to the private warrants during those periods.

Investment impairment: Investment impairment of $3,705 charged in connection with the sale of the Cansativa shares for the three months ended September 30, 2023. The Company compared the subsequent transaction value of the shares sold to the carrying value and the impairment loss of $3,705 was recorded in the consolidated statement of operations during the three months ended September 30, 2023.

Foreign exchange loss. The impact of foreign exchange for the three months ended September 30, 2023 was a loss of $275, as compared to a loss of $669 for the three months ended September 30, 2022. The foreign exchange losses for the three months ended September 30, 2023, were primarily driven by the currency fluctuations of the Euro versus the U.S. Dollar.

Other expense, net. Other expense, net includes items not individually material to our consolidated financial statements.

Table of Contents

Nine Months Ended September 30, 2023 compared to nine months ended September 30, 2022

Interest and amortization of debt issuance cost, net. Interest and amortization of debt issuance cost, net for the nine months ended September 30, 2023 decreased to $23, as compared to $2,696 for the nine months ended September 30, 2022. The decrease was primarily due to writing off of debt discount costs recognized in connection with the beneficial conversion factor related to the Catalina LP Convertible Note issued in connection with the Notes Purchase Agreement, dated July 19, 2021 (the “Catalina Note”) and the Loan and Security Agreement, dated May 3, 2019 in the comparable prior year period, which were fully re-paid in the fiscal year ended December 31, 2022.

Gain on remeasurement of warrant liability. Gain on remeasurement of warrant liability was $5 for the nine months ended September 30, 2023, as compared to a loss of $2,009 for the nine months ended September 30, 2022. The gain and loss are directly attributable to the remeasurement of the warrant liability as of September 30, 2023 and September 30, 2022, respectively, due to the change in the underlying value related to the private warrants during those periods.

Gain on investments. Gain on investments for the nine months ended September 30, 2023 was nil, as compared to $6,851 for the nine months ended September 30, 2022. The gain on investments in 2022 was related to the sale of Cansativa shares to an unrelated third-party and the revaluation of the Company's retained interest of the shares still held.

Loss on debt extinguishment, net. Net loss on debt extinguishment was nil for the nine months ended September 30, 2023 compared to $2,263 for the nine months ended September 30, 2022. The loss was primarily related to the debt extinguishment as a result of the amendment of the Catalina Note on January 13, 2022.

Investment impairment: Investment impairment of $3,705 charged in connection with the sale of the Cansativa shares for the nine months ended September 30, 2023. The Company compared the subsequent transaction value of the shares sold to the carrying value and the impairment loss of $3,705 was recorded in the consolidated statement of operations during the nine months ended September 30, 2023.

Foreign exchange loss. The impact of foreign exchange for the nine months ended September 30, 2023 was a loss of $297, as compared to a loss of $1,144 for the nine months ended September 30, 2022. The foreign exchange losses for the nine months ended September 30, 2023, were primarily driven by the currency fluctuations of the Euro versus the U.S. Dollar.

Other expense, net. Other expenses, net includes items not individually material to our consolidated financial statements.

Operating Results by Business Segment

Our management evaluates segment profit/loss for each of our reportable segments. We define segment profit/loss as income from continuing operations before interest, taxes, depreciation, amortization, share-based compensation expense, gains/losses on foreign currency fluctuations, gains/losses on the early extinguishment of debt and miscellaneous expenses. Segment profit/loss also excludes the impact of certain items that are not directly attributable to the reportable segments’ underlying operating performance. For a reconciliation of segment profit to loss from continuing operations before income taxes, see Note 16 to our unaudited condensed consolidated interim financial statements for the three months ended September 30, 2023 included in this Form 10-Q.

Revenue by segment

(In thousands of U.S. dollars)


	Three months ended September 30,				Nine Months Ended September 30,
	2023		2022 (*)		2023		2022 (*)
Segment Revenue:
Cannabinoid	$	1,442	$	613	$	4,537	$	3,166
Non-Cannabinoid	2,378		2,254		8,242		8,842
Total revenue	$	3,820	$	2,867	$	12,779	$	12,008

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

Table of Contents

Cannabinoid. Cannabinoid revenue increased to $1,442 for the three months ended September 30, 2023, as compared to $613 for the three months ended September 30, 2022. For the nine months ended September 30, 2023, Cannabinoid revenue increased to $4,537 as compared to $3,166 for the nine months ended September 30, 2022. The increases in cannabinoid segment revenues were primarily driven by increased sales efforts for the Company’s extract products, particularly in Brazil, Australia, and Israel.

Non-Cannabinoid. Non-Cannabinoid revenue increased to $2,378 for the three months ended September 30, 2023, as compared to $2,254 the three months ended September 30, 2022. The increase in non-cannabinoid revenues was due to improved demand in the segment’s specialty channel during the quarter. For the nine months ended September 30, 2023, non-cannabinoid revenue decreased to $8,242 as compared to $8,842 for the nine months ended September 30, 2022. The decrease in non-cannabinoid revenues was due to continued demand headwinds in the segment’s specialty channel, which resulted in lower inventory orders during the nine months ended September 30, 2023.

Segment profit/loss

(In thousands of U.S. dollars)



	Three months ended September 30,				Change
	2023		2022 (*)		$	%
Segment Profit/(Loss):
Cannabinoid	$	(2,225)	$	(2,732)	507	(19)	%
Non-Cannabinoid	316		95		221	233	%
Total Segment Loss (a)	$	(1,909)	$	(2,637)	728	(28)	%



	Nine Months Ended September 30,				Change
	2023		2022 (*)		$	%
Segment Profit/(Loss):
Cannabinoid	$	(6,237)	$	(11,144)	4,907	(44)	%
Non-Cannabinoid	1,594		1,109		485	44	%
Total Segment Loss (a)	$	(4,643)	$	(10,035)	5,392	(54)	%

(a) For a reconciliation of segment (loss) to loss before income taxes see Note 16 to our unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2023, included in this Form 10-Q.

Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

Cannabinoid — Cannabinoid segment loss decreased to $2,225 for the three months ended September 30, 2023 compared to a loss of $2,732 for the three months ended September 30, 2022, primarily due to the decrease in expenses related to the effective implementation of cost-cutting measures.

Cannabinoid segment loss decreased to $6,237 for the nine months ended September 30, 2023 compared to a loss of $11,144 for the nine months ended September 30, 2022, primarily due to the effective implementation of cost-cutting measures.

Non-Cannabinoid — Non-Cannabinoid segment profit increased to $316 for the three months ended September 30, 2023, compared to a profit of $95 for the three months ended September 30, 2022. The increase was primarily attributable to decreased payroll related costs, sales and marketing costs and marginal increase in revenue

Non-Cannabinoid segment profit increased to $1,594 for the nine months ended September 30, 2023, compared to a profit of $1,109 for the nine months ended September 30, 2022. The increase was primarily attributable to decreased payroll related costs and sales and marketing costs.

Table of Contents

Liquidity and Capital Resources

We are actively seeking sources of financing or proceeds from sales of assets to fund our continued operations. There can be no assurance that we will be able to complete any financing or asset sale transaction in a timely manner or on acceptable terms or otherwise. If we are not able to raise additional cash, we may be forced to suspend or curtail planned programs, or cease operations altogether.

The following table sets forth the major components of our Consolidated Statements of Cash Flows for the periods presented:

(In thousands of U.S. dollars)


	Nine months ended September 30,
		2023		2022
Net cash used in operating activities		$	(9,965)	$	(23,969)
Net cash provided by investing activities		2,638		642
Net cash provided by financing activities		818		3,539
Effect of foreign currency translation on cash and cash equivalents		159		(304)
Cash, cash equivalents, and restricted cash beginning of period		12,888		37,699
Cash, cash equivalents, and restricted cash end of period		6,538		17,607
Decrease in cash and cash equivalents		$	(6,350)	$	(20,092)

Cash flows used in operating activities

The decrease in net cash used in operating activities during the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022, was primarily the result of decreased operating and other expenses due to implementation of a decrease in our loss on investments, decreased share-based compensation expense and changes in operating assets and liabilities.

Cash flows from investing activities

The increase in net cash provided by investing activities during the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022, was primarily due to net cash provided by proceeds from the sale of fixed assets from our discontinued operations in Portugal in 2023. During the nine months ended September 30, 2022, net cash provided was primarily due to proceeds from partial sale of equity method of investments as offset by purchase of fixed assets.

Cash flows from financing activities

The decrease in net cash provided by financing activities during the nine months ended September 30, 2023 was primarily driven by the net proceeds from issuance of shares under the Equity Distribution Agreement as offset by repayment of debt. Net cash provided by financing activities during the nine months ended September 30, 2022 was due to issuance of shares as offset by repayment of substantial outstanding debt in the nine months ended September 30, 2022.

Sources of Liquidity

We have historically financed our operations through the issuance of shares, the issuance of convertible debt and cash from operations. As of September 30, 2023 and December 31, 2022, we had cash and cash equivalents (excluding restricted cash) of $6,472 and $12,449, respectively, which were held for working capital, repayment of loans and general corporate purposes. This represents an overall decrease of $7,372.

Table of Contents

through the Agent. The issuance and sale of the common shares under the Equity Distribution Agreement have been made, and any such future sales will be made, pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-262183), which includes an “at-the-market” (“ATM”) offering prospectus supplement (the "Prospectus Supplement"), as amended from time to time.

We have had operating losses and negative cash flows from operations since inception and expect to continue to incur net losses for the foreseeable future until such time, if ever, that we can generate significant revenue from the sale of our available inventories. We anticipate that we will continue to incur losses from operations due to pre-commercialization activities, marketing and manufacturing activities, and general and administrative costs to support operations.

We have historically been able to manage liquidity requirements through cost management and cost reduction measures, supplemented with raising additional financing and proceeds from the sale of assets. While we have been successful in raising financing in the past, there can be no assurances that additional financing will be available when needed on acceptable terms, or at all. The continued influence of the direct and indirect results of the outbreak of COVID-19 and uncertain market and regulatory conditions may further limit our ability to access capital. If we are not able to secure adequate additional funding or sell additional assets, we may be forced to make reductions in spending, extend payment terms with suppliers, and suspend or curtail planned programs. Any of these actions could materially harm our business, results of operations, financial condition, and prospects.

Uses of Liquidity

Our primary need for liquidity is to fund working capital requirements, capital expenditures, debt service obligations and for general corporate purposes. Our ability to fund operations, make planned capital expenditures and service debt obligations depends on future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business and other factors. Our interim financial statements have been prepared on a going concern basis, which assumes that we will continue to be in operation for the foreseeable future and, accordingly, will be able to realize our assets and discharge our liabilities in the normal course of operations as they come due.

We manage our liquidity risk by preparing budgets and cash forecasts to ensure we have sufficient funds to meet obligations. In managing working capital, we may limit the amount of our cash needs by selling inventory at wholesale rates, pursuing additional financing sources, and managing the timing of capital expenditures.

However, the Company's current working capital needs, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the issuance date of the interim financial statements. The consolidated financial statements do not include any adjustments for the recovery and

classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to

continue as a going concern.

The Company’s ability to execute its operating plans through 2023 and beyond depends on its ability to obtain additional funding, which may include several initiatives such as raising capital, reducing working capital, and monetizing non-core assets to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all.

Debt

Total debt outstanding as of September 30, 2023 and December 31, 2022 was $1,336 and $1,530, respectively. The debt outstanding as of September 30, 2023 was comprised of our current and non-current portions of borrowings of $477 and $859, respectively, related to the Colombia and Portugal working capital loans. The debt outstanding as of September 30, 2023 was comprised of our current and non-current portions of other borrowings of $477 and $859, respectively, related to the Colombia and Portugal working capital loans. The debt outstanding as of December 31, 2022 was comprised of our current and non-current portions of other borrowings of $465 and $1,065, respectively, related to the Colombia and Portugal working capital

Table of Contents

loans. For more information refer to Note 10 to our unaudited condensed consolidated interim financial statements for the period ended of September 30, 2023 included in this Form 10-Q.

Portugal Debt

For the three months ended September 30, 2023 and 2022, the company recognized interest expense of approximately €11 ($12) and €7 ($7), respectively, and repaid principal of approximately €63 ($68) and €63 ($63), respectively, of the Portugal Debt in accordance with the terms of the loan agreement. For the nine months ended September 30, 2023, the company recognized interest expense of approximately €31 ($33) and €22 ($24), respectively, and repaid principal of approximately €188 ($201) and €188 ($200), respectively, of the Portugal Debt in accordance with the terms of the loan agreement. As of September 30, 2023 and December 31, 2022, the outstanding principal balance of the Portugal Debt was €563 ($604) and €875 ($1,076), respectively.

Colombia Debt

Contingencies

In the normal course of business, we receive inquiries or become involved in legal disputes regarding various litigation matters. Other than as disclosed in Item 1A Risk Factor of this Form 10-Q and except for the matter as discussed below, in the opinion of management, as of September 30, 2023 any potential liabilities resulting from claims we have received would not have a material adverse effect on our consolidated financial statements.

On July 1, 2023, an APA was entered into by and among the Company as guarantor, Clever Leaves Portugal a wholly-owned subsidiary of the Company, as the seller, and Terra Verde, Lda. as the purchaser a wholly-owned subsidiary of Curaleaf International, part of Curaleaf Holdings, Inc. Pursuant to the APA, the Purchaser agreed to acquire, and the Seller agreed to sell, certain laboratory and processing equipment for the production of cannabinoid products, as well as informational rights to policies and procedures for the production and manufacture of such cannabinoids that the Seller used in its EU-GMP certified cannabis processing facility in Setubal, Portugal. Under the terms of the APA, the Company has provided a guarantee in case of malfunctioning of the equipment for a period of 12 months expiring July 2024. The total amount of the guarantee will not exceed, in any circumstances, €500 and undertakes the obligation of principal payor renouncing to the benefit of prior foreclosure of the Seller’s assets. The Company considers the probability of requiring payment under the guarantee to be remote. Hence, no liabilities or expenses are recorded in the financial statements.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements during the periods presented, other than as discussed above.

Table of Contents

Critical Accounting Policies and Significant Judgments and Estimates

See Part II, Item 7, "Critical Accounting Policies and Estimates" in our 2022 Form 10-K. There have been no material changes to our critical accounting policies and estimates since our 2022 Form 10-K except as described below.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Controls and Procedures

Management, with the participation of the Company's Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of as September 30, 2023. The term "disclosure control and procedures" as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of September 30, 2023 were not effective due to a material weakness as described below.

Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting

Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the control may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.

Material Weakness in Internal Control over Financial Reporting

As initially reported in the Annual Report on Form 10-K for the year ended December 31, 2020, Management did not maintain effective control environment attributed to the following:

•The Company's insufficient number of trained professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately.

•Insufficient segregation of duties, lack of structure, reporting lines and appropriate authorities and responsibilities to achieve financial reporting objectives. Lack of evidence to support the performance of controls and the adequacy of review procedures, including the completeness and accuracy of information used in the performance of controls.

During the year ended December 31, 2022, an additional material weakness was identified as follows:

•Information technology general controls were not properly designed and implemented in user access over certain information technology systems that support the Company's financial reporting process. The access issues relate to the extent of privileges afforded to certain users as well as the Company's user access review controls.

Management Plan to Remediate Material Weaknesses

During the year ended December 31, 2022 and the nine months ended September 30, 2023, we made the following enhancements to our control environment:

a. We enhanced our controls to improve the preparation and review over complex accounting measurements, and the application of GAAP to significant accounts and transactions, and our financial statement disclosures; and,

Table of Contents

b. We engaged outside consultants to assist us in our evaluation of the design, implementation, and documentation of internal controls that address the relevant risks, and that provide for appropriate evidence of performance of our internal controls (including completeness and accuracy procedures) and to provide technical Sarbanes-Oxley Act training to individuals throughout the organization that are responsible for executing internal controls.

Our remediation activities are ongoing during calendar year 2023. In addition to the above actions, we expect to engage in additional activities, including, but not limited to:

a. Adding more technical accounting resources to enhance our control environment and to allow for proper segregation of duties;

b. Enhance the Company's accounting software system with a system designed with the functionality to properly segregate duties and implement appropriate user access controls;

c. Until we have sufficient technical accounting resources, we will continue to engage external consultants to provide support and to assist us in our evaluation of more complex applications of GAAP, and to assist us with documenting and assessing our accounting policies and procedures; and,

d. Engaging outside consultants to assist us in performing testing in order to evaluate the operating effectiveness of our internal controls.

Under the direction of the audit committee of the board of directors, management will continue to take measures to remediate the material weaknesses in calendar year 2023. As such, we will continue to enhance corporate oversight over process-level controls and structures to ensure that there is appropriate assignment of authority, responsibility, and accountability to enable remediation of our material weaknesses. We believe that our remediation plan will be sufficient to remediate the identified material weaknesses and strengthen our internal control over financial reporting.

We believe the corrective actions and controls need to be in operation for a sufficient period for management to conclude that the control environment is operating effectively and has been adequately tested through audit procedures. Therefore, the material weaknesses have not been remediated as of the date of this report.

Changes in Internal Control over Financial Reporting

The Company is in the process of implementing certain changes in its internal controls to remediate the material weakness described above. Except as noted above, no change to our internal control over financial reporting occurred during the three months ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Part II - OTHER INFORMATION

Item 1. Legal Proceedings

We are involved in various investigations, claims and lawsuits arising in the normal conduct of our business, none of which, in our opinion, will have a material adverse effect on our financial condition, results of operations, or cash flows. We cannot assure you that we will prevail in any litigation. Regardless of the outcome, any litigation may require us to incur significant litigation expense and may result in significant diversion of management attention.

Item 1A. Risk Factors

The following discussion supplements the discussion of risk factors affecting the Company as set forth in Part I, Item 1A, “Risk Factors” in our 2022 Form 10-K and Cautionary Note Regarding Forward-Looking Statements on page 4 of this Form 10-Q. The discussion of risk factors, as so supplemented, sets forth the material risk factors that could affect the Company’s financial condition and operations. Readers should not consider any descriptions of such factors to be a complete set of all potential risks that could affect the Company.

Conditions in Israel, including the recent attack by Hamas, has limited our ability to market and sell our products in Israel and, as a result, may adversely affect our results of operations.

Israel is one of our five key markets. As a result, our business and operations are directly affected by economic, political, geopolitical and military conditions affecting Israel. On October 7, 2023, Hamas militants infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Thereafter, extensive rocket attacks on Israel resulted in a declaration of war by the Israeli government.

The intensity and duration of this war, and its resulting impact on our company, is difficult to predict. Within a matter of days, the value of Israeli currency decreased to the point that its Central Bank took steps to protect it from collapse. These events may imply wider macroeconomic indications of a deterioration in Israel’s economic standing, which may have a negative impact on demand for our products from within the region. Such a decrease in demand would have a material adverse effect on our business and results of operations.

In addition to any potential decrease in demand, distributing our products into the region has become more difficult. In the immediate aftermath of the Hamas attack, many freight companies temporarily halted shipments to Israel. There can be no guarantee that these or other distribution chain disruptions will not occur in the future. Distribution to the region could also incur greater costs as a result of the emergency conditions in the region. Any impact to our distribution logistics and network in the region could have a material adverse effect on our business and results of operations.

The Reverse Share Split may adversely impact the liquidity of our common shares and warrants and may not be effective in facilitating our efforts to maintain compliance with the continued listing requirements of Nasdaq.

The liquidity of our common shares and warrants may be adversely affected by the Reverse Share Split, given the significantly reduced number of common shares that are outstanding following its effectiveness. In addition, there can be no assurance that the trading price of our common shares will remain at or above $1.00 per share.

In addition, the Reverse Share Split has resulted in some shareholders owning “odd lots” of less than 100 common shares on a post-reverse share split basis. Odd lots may be more difficult to sell, or require greater transaction costs per share to sell, than shares in “round lots” of even multiples of 100 shares.

The Reverse Share Split was effected to regain compliance with Nasdaq'sminimum bid price requirement of at least $1.00 per share. However, there can be no assurance that we will maintain compliant with such requirement, or that , we will not become deficient with respect to other Nasdaq listing requirements following, or as a result of, the Reverse Share Split.

Failure to resolve a dispute regarding the alleged default under Herbal Brands’ lease agreement for its facilities in Tempe, Arizona could have a material adverse effect on the Company.

Herbal Brands is currently in dispute with Double G Enterprises, LLC (“Double G”), the landlord for the facility out of which Herbal Brands conducts substantially all of its operations, including the manufacture and distribution of Herbal Brands’ products, regarding the lease between Double G and Herbal Brands. Double G has alleged that Herbal Brands is in default under the lease agreement’s “change of control” provision, suggesting that more than 49% of the ownership interest in Herbal

Table of Contents

Brands has been transferred without Double G’s prior written consent, in contravention of the lease terms. Double G sent a letter noticing acceleration of all future rents due under the lease (approximately $460,000) and termination of the right to possess the premises. Double G has not provided a basis for its claim regarding Herbal Brands’ transfer of ownership. Herbal Brands was acquired by us prior to entering into the lease agreement. No action has been filed in any court, in any jurisdiction, for this dispute. Even though we believe that Herbal Brands is presently in compliance with all material provisions of its lease with Double G, there can be no assurance that this dispute will be resolved in our favor. If this dispute evolves to require formal dispute resolution there is no guarantee that it will be decided that Herbal Brands is not in default. In the event that Herbal Brands is found to be in default, and the actions we take are not sufficient to cure the default raised by Double G, the remedies available to Double G may include acceleration of all future rents under the lease agreement and/or termination of the lease. The lease is set to expire in April 2024. Acceleration of rents due and early termination of the lease would significantly reduce the value of Herbal Brands’ operations, and would materially curtail, if not completely eliminate, our ability to obtain revenues from Herbal Brands.

Item 5. Other Information

Not applicable.

Item 6. Exhibits


Exhibit No.						Description
3.1						Amended and Restated Articles of Clever Leaves Holdings Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the SEC by Clever Leaves Holdings Inc. on December 23, 2020).
4.2						Specimen Common Share Certificate of Clever Leaves Holdings Inc. (incorporated by reference to Exhibit 4.1 to the Current Report on Form 10-Q filed with the SEC by Clever Leaves Holdings Inc. on May 17, 2021).
4.3						Specimen Warrant Certificate of Clever Leaves Holdings Inc. (incorporated by reference to Exhibit 4.5 to Amendment No. 2 to the Registration Statement on Form S-4 (File No. 333-241707) filed with the SEC by Clever Leaves Holdings Inc. on November 9, 2020).
4.4						Warrant Agreement, dated December 10, 2018, between Schultze Special Purpose Acquisition Corp. and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 of Schultze Special Purpose Acquisition Corp.’s Current Report on Form 8-K, filed with the SEC on December 14, 2018).
4.5						Assignment, Assumption and Amendment Agreement, dated as of December 18, 2020, among Clever Leaves Holdings Inc., Schultze Special Purpose Acquisition Corp. and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.4 of the Current Report on Form 8-K filed with the SEC by Clever Leaves Holdings Inc. on December 28, 2020).
4.6						Waiver of Certain Rights, dated February 2, 2022, between Schultze Special Purpose Acquisition Sponsor, LLC and Clever Leaves Holdings Inc. (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8_K filed with the SEC by Clever Leaves Holdings Inc. on February 2, 2022.
4.7						Assignment, Assumption and Amendment Agreement No. 2, dated as of April 12, 2021, among Clever Leaves Holdings Inc., Continental Stock Transfer & Trust Company and Computershare Inc. (incorporate by reference to Exhibit 4.3 to Current Report on Form 10-Q file with the SEC by Clever Leaves Holdings, Inc. on May 17, 2021).
10.1						Asset Purchase Agreement dated July 1, 2023, by and among Clever Leaves Holdings Inc., Clever Leaves Portugal Unipessoal, Lda. and Terra Verde, Lda. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed with the SEC by on Clever Leaves Holdings Inc. on July 5, 2023)
10.2						First Share Purchase and Transfer Agreement, dated October 17, 2023, by and among Northern Swan Deutschland Holdings, Inc., Cansativa GmbH and EIP Entrepreneurial Investment GmbH (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K file with the SEC by Clever Leaves Holdings Inc.
31.1**						Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2**						Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1***						Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS						Inline XBRL Instance Document
101.SCH						Inline XBRL Taxonomy Schema Linkbase Document
101.CAL						Inline XBRL Taxonomy Calculation Linkbase Document
101.DEF						Inline XBRL Taxonomy Definition Linkbase Document
101.LAB						Inline XBRL Taxonomy Labels Linkbase Document
101. PRE						Inline XBRL Taxonomy Presentation Linkbase Document
104						Cover Page Interactive Date File - (formatted as Inline XBRL and contained in Exhibit 101)

** Filed herewith

*** Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Clever Leaves Holdings Inc.
November 9, 2023
	By:	/s/ Henry R. Hague, III
	Name:	Henry R. Hague, III
	Title:	Chief Financial Officer
		(Authorized Officer and Principal Financial Officer)

Exhibit 31.1

CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andres Fajardo, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Clever Leaves Holdings Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 3a-15(f) and 15d-15(f)) for the registrant and have:

(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023


						/s/ Andres Fajardo
						Andres Fajardo
						Chief Executive Officer

Exhibit 31.2

CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Henry R. Hague, III, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Clever Leaves Holdings Inc.;

(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 9, 2023


						/s/ Henry R. Hague, III
						Henry R. Hague, III
						Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Clever Leaves Holdings Inc., a corporation organized under the laws of British Columbia, Canada (the “Company”), on Form 10-Q for the quarter ending September 30, 2023 as filed with the U.S. Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company does hereby certify, pursuant to 18 U.S.C. § 1350 (section 906 of the Sarbanes-Oxley Act of 2002), that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 9, 2023						/s/ Andres Fajardo
						Andres Fajardo
						Chief Executive Officer


Date: November 9, 2023						/s/ Henry R. Hague, III
						Henry R. Hague, III
						Chief Financial Officer

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 07, 2023
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-39820
Entity Registrant Name	Clever Leaves Holdings Inc.
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	Bodega 19-B Parque Industrial Tibitoc P.H
Entity Address, City or Town	Tocancipá - Cundinamarca
Entity Address, Country	CO
Entity Address, Postal Zip Code	N/A
City Area Code	561
Local Phone Number	634-7430
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		1,745,152
Entity Central Index Key	0001819615
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Common shares without par value
Entity Information [Line Items]
Title of 12(b) Security	Common shares without par value
Trading Symbol	CLVR
Security Exchange Name	NASDAQ
Warrants, each warrant exercisable for 1/30th common share at an exercise price of $11.50
Entity Information [Line Items]
Title of 12(b) Security	Warrants, each warrant exercisable for 1/30th common share at an exercise price of $11.50
Trading Symbol	CLVRW
Security Exchange Name	NASDAQ

Condensed Consolidated Statements of Financial Position - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current:
Cash and cash equivalents	$ 6,472	$ 12,449
Restricted cash	66	439
Accounts receivable, net	1,746	2,252
Prepaids, deposits and other receivables	1,941	2,708
Inventories, net	7,709	8,399
Total current assets	17,934	26,247
Investment – Cansativa	1,896	5,679
Property, plant and equipment, net of accumulated depreciation of $8,389 and $7,120 for September 30, 2023 and December 31, 2022, respectively	12,752	13,963
Assets held for sale - Land	1,500	1,500
Intangible assets, net	2,821	3,354
Operating lease right-of-use assets, net	820	1,303
Other non-current assets	54	52
Total Assets	37,777	52,098
Current:
Accounts payable	2,088	2,299
Accrued expenses and other current liabilities	3,225	4,238
Loans and borrowings, current portion	477	465
Warrant liability	108	113
Operating lease liabilities, current portion	512	1,239
Deferred revenue	437	1,072
Total current liabilities	6,847	9,426
Loans and borrowing — long-term	859	1,065
Operating lease liabilities — long-term	366	1,087
Other long-term liabilities	16	112
Total Liabilities	8,088	11,690
Contingencies and commitments
Shareholders’ equity
Preferred shares, without par value, unlimited shares authorized, nil shares issued and outstanding for each of September 30, 2023 and December 31, 2022	0	0
Common shares, without par value, unlimited shares authorized: 1,726,145 and 1,454,559 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	0	0
Additional paid-in capital	223,407	221,313
Accumulated deficit	(193,718)	(180,905)
Total shareholders' equity	29,689	40,408
Total liabilities and shareholders' equity	$ 37,777	$ 52,098

Condensed Consolidated Statements of Financial Position (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Property, plant and equipment, accumulated depreciation	$ 8,389	$ 7,120
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, shares issued (in shares)	1,726,145	1,454,559
Common stock, shares outstanding (in shares)	1,726,145	1,454,559

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue, net	$ 3,820,000	$ 2,867,000	$ 12,779,000	$ 12,008,000
Cost of sales	(1,878,000)	(1,568,000)	(5,877,000)	(5,635,000)
Gross profit	1,942,000	1,299,000	6,902,000	6,373,000
Expenses
General and administrative	4,155,000	5,442,000	14,327,000	18,865,000
Sales and marketing	582,000	615,000	1,600,000	2,075,000
Research and development	292,000	343,000	907,000	1,114,000
Restructuring expenses	0	(82,000)	0	3,761,000
Goodwill impairment		19,000,000		19,000,000
Depreciation and amortization	290,000	305,000	750,000	950,000
Total expenses	5,319,000	25,623,000	17,584,000	45,765,000
Loss from operations	(3,377,000)	(24,324,000)	(10,682,000)	(39,392,000)
Other Expense (Income), net
Interest and amortization of debt issuance cost	5,000	(58,000)	23,000	2,696,000
Gain on remeasurement of warrant liability	(60,000)	(196,000)	(5,000)	(2,009,000)
Gain on investment	0	0	0	(6,851,000)
Investment impairment	3,705,000	0	3,705,000	0
Loss on debt extinguishment, net	0	0	0	2,263,000
Foreign exchange loss	275,000	669,000	297,000	1,144,000
Other (income) expense, net	(31,000)	102,000	(19,000)	111,000
Total other expenses (income), net	3,894,000	517,000	4,001,000	(2,646,000)
Loss before income taxes and equity investment loss	(7,271,000)	(24,841,000)	(14,683,000)	(36,746,000)
Deferred income tax (recovery)	0	(6,650,000)	0	(6,650,000)
Equity investment share of loss	0	0	0	64,000
Loss from continuing operations	(7,271,000)	(18,191,000)	(14,683,000)	(30,160,000)
Income (loss) from discontinued operations	2,133,000	(1,972,000)	1,869,000	(7,189,000)
Net loss	$ (5,138,000)	$ (20,163,000)	$ (12,814,000)	$ (37,349,000)
Net loss per share:
Basic from continuing operations (USD per share)	$ (4.60)	$ (12.93)	$ (9.70)	$ (24.70)
Diluted from continuing operations (USD per share)	(4.60)	(12.93)	(9.70)	(24.70)
Basic from discontinued operations (USD per share)	1.35	(1.41)	1.23	(5.90)
Diluted from discontinued operations (USD per share)	1.35	(1.41)	1.23	(5.90)
Net loss per share - basic (USD per share)	(3.25)	(14.33)	(8.47)	(30.59)
Net loss per share - diluted (USD per share)	$ (3.25)	$ (14.33)	$ (8.47)	$ (30.59)
Weighted-average common shares outstanding - basic (in shares)	1,580,456	1,407,419	1,513,575	1,221,107
Weighted-average common shares outstanding - diluted (in shares)	1,580,456	1,407,419	1,513,575	1,221,107
Weighted-average common shares outstanding per share, basic (USD per share)	$ (3.25)	$ (14.33)	$ (8.47)	$ (30.59)
Weighted-average common shares outstanding per share, diluted (USD per share)	$ (3.25)	$ (14.33)	$ (8.47)	$ (30.59)

Condensed Consolidated Statements of Shareholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		886,860
Beginning balance at Dec. 31, 2021	$ 72,770	$ 0	$ 187,510	$ (114,740)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of common shares, gross (in shares)		368,252
Issuance of common shares, gross	23,400		23,400
Issuance of common shares upon vesting RSUs (in shares)		8,248
Stock option exercise (in shares)		3,870
Stock option exercise	22		22
Stock-based compensation expense	500		500
Equity issuance costs	(1,177)		(1,177)
Beneficial conversion feature of Convertible Note	1,749		1,749
Conversion of Convertible Note to common shares (in shares)		20,233
Conversion of Convertible Note to common shares	1,324		1,324
Net loss	(16,140)			(16,140)
Ending balance (in shares) at Mar. 31, 2022		1,287,463
Ending balance at Mar. 31, 2022	82,448	$ 0	213,328	(130,880)
Beginning balance (in shares) at Dec. 31, 2021		886,860
Beginning balance at Dec. 31, 2021	72,770	$ 0	187,510	(114,740)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net loss	(37,349)
Ending balance (in shares) at Sep. 30, 2022		1,452,380
Ending balance at Sep. 30, 2022	69,502	$ 0	221,591	(152,089)
Beginning balance (in shares) at Mar. 31, 2022		1,287,463
Beginning balance at Mar. 31, 2022	82,448	$ 0	213,328	(130,880)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of common shares upon vesting RSUs (in shares)		1,330
Stock option exercise (in shares)		1,186
Stock-based compensation expense	1,148		1,148
Conversion of Convertible Note to common shares (in shares)		30,000
Conversion of Convertible Note to common shares	2,039		2,039
Net loss	(1,046)			(1,046)
Ending balance (in shares) at Jun. 30, 2022		1,319,979
Ending balance at Jun. 30, 2022	84,589	$ 0	216,515	(131,926)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of common shares, gross (in shares)		131,573
Issuance of common shares, gross	4,286		4,286
Issuance of common shares upon vesting RSUs (in shares)		828
Stock-based compensation expense	958		958
Equity issuance costs	(168)		(168)
Net loss	(20,163)			(20,163)
Ending balance (in shares) at Sep. 30, 2022		1,452,380
Ending balance at Sep. 30, 2022	$ 69,502	$ 0	221,591	(152,089)
Beginning balance (in shares) at Dec. 31, 2022	1,454,559	1,454,559
Beginning balance at Dec. 31, 2022	$ 40,408	$ 0	221,313	(180,905)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of common shares upon vesting RSUs (in shares)		12,350
Stock-based compensation expense	468		468
Equity issuance costs	(25)		(25)
Net loss	(4,081)			(4,081)
Ending balance (in shares) at Mar. 31, 2023		1,466,909
Ending balance at Mar. 31, 2023	$ 36,770	$ 0	221,756	(184,986)
Beginning balance (in shares) at Dec. 31, 2022	1,454,559	1,454,559
Beginning balance at Dec. 31, 2022	$ 40,408	$ 0	221,313	(180,905)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Net loss	$ (12,814)
Ending balance (in shares) at Sep. 30, 2023	1,726,145	1,726,145
Ending balance at Sep. 30, 2023	$ 29,689	$ 0	223,407	(193,718)
Beginning balance (in shares) at Mar. 31, 2023		1,466,909
Beginning balance at Mar. 31, 2023	36,770	$ 0	221,756	(184,986)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of common shares, gross (in shares)		51,986
Issuance of common shares, gross	438		438
Issuance of common shares upon vesting RSUs (in shares)		4,587
Stock-based compensation expense	433		433
Equity issuance costs	(97)		(97)
Net loss	(3,595)			(3,595)
Ending balance (in shares) at Jun. 30, 2023		1,523,482
Ending balance at Jun. 30, 2023	33,949	$ 0	222,530	(188,581)
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Issuance of common shares, gross (in shares)		201,912
Issuance of common shares, gross	903		903
Issuance of common shares upon vesting RSUs (in shares)		738
Stock-based compensation expense	52		52
Equity issuance costs	(77)		(77)
Round off due to reverse split (in shares)		13
Net loss	$ (5,138)			(5,138)
Ending balance (in shares) at Sep. 30, 2023	1,726,145	1,726,145
Ending balance at Sep. 30, 2023	$ 29,689	$ 0	$ 223,407	$ (193,718)

Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2023

Mar. 31, 2023

Sep. 30, 2022

Mar. 31, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Cash Flow from Operating Activities:

Loss from continuing operations

$ (7,271)

$ (18,191)

$ (14,683)

$ (30,160)

Gain (loss) from discontinued operations

2,133

(1,972)

1,869

(7,189)

Net loss

(5,138)

$ (4,081)

(20,163)

$ (16,140)

(12,814)

(37,349)

Adjustments to reconcile to net cash used in operating activities:

Depreciation and amortization

1,933

2,935

Gain on sale of fixed assets

(2,825)

Amortization of debt discount and debt issuance cost

1,949

Inventory provision

591

3,822

Restructuring and related costs

3,791

Gain on remeasurement of warrant liability

(5)

(2,009)

Intangible asset impairment

19,000

Deferred tax recovery

(6,650)

$ 6,650

Amortization of right of use asset

483

128

Foreign exchange loss

341

1,420

Stock-based compensation expense

954

2,606

Investment impairment

3,705

Equity investment share of loss

Gain on investment

(6,851)

Loss on debt extinguishment, net

2,263

Other non-cash expense, net

600

Changes in operating assets and liabilities:

Decrease (increase) in accounts receivable

506

(369)

Decrease (increase) in prepaid expenses and other receivables

767

(466)

(Increase) decrease in other non-current assets

(638)

555

(Decrease) in lease liability

(788)

Decrease (increase) in inventory

(5,067)

(Decrease) in accounts payable and other current liabilities

(2,178)

(4,756)

(Decrease) increase in accrued and other non-current liabilities

(96)

415

Net cash used in operating activities

(9,965)

(23,969)

Cash Flow from Investing Activities:

Proceeds from sale of fixed assets

2,825

Purchase of property, plant and equipment

(187)

(1,856)

Proceeds from partial sale of equity method of investment

2,498

Net cash provided by investing activities

2,638

642

Cash Flow from Financing Activities:

Repayment of debt

(323)

(22,897)

Other borrowings

Proceeds from issuance of shares

1,340

27,686

Equity issuance costs

(199)

(1,345)

Stock option exercise

Net cash provided by financing activities

818

3,539

Effect of exchange rate changes on cash, cash equivalents & restricted cash

159

(304)

Decrease in cash, cash equivalents & restricted cash

(6,350)

(20,092)

Cash, cash equivalents & restricted cash, beginning of period

^[1]

$ 12,888

$ 37,699

12,888

37,699

Cash, cash equivalents & restricted cash, end of period

^[1]

$ 6,538

$ 17,607

$ 6,538

$ 17,607

$ 12,888

[1]	These amounts include restricted cash of $66 and $454 as of September 30, 2023 and September 30, 2022, respectively, which are comprised primarily of cash on deposits for certain lease arrangements.

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Statement of Cash Flows [Abstract]
Restricted cash	$ 66	$ 439	$ 454

CORPORATE INFORMATION	9 Months Ended
CORPORATE INFORMATION	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CORPORATE INFORMATION	CORPORATE INFORMATION Clever Leaves Holdings Inc., (the “Company”) is a multi-national U.S. based holding company focused on cannabinoids. In addition to the cannabinoid business, the Company is also engaged in the non-cannabinoid business of nutraceutical and other natural remedies and wellness products. The Company is incorporated under the Business Corporations Act of British Columbia, Canada. The mailing address of the Company's principal executive office is Bodega 19-B Parque Industrial Tibitoc P.H, Tocancipá - Cundinamarca, Colombia.

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying interim condensed consolidated financial statements (“Financial Statements”) are unaudited. These Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of regulation S-X. Accordingly, they do not include all disclosures required for annual financial statements. These Financial Statements reflect all adjustments, which, in the opinion of the management, are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances have been eliminated. All adjustments were of a normal recurring nature. Interim results are not necessarily indicative of results to be expected for the full year. The Financial Statements include the accounts of the Company and its wholly owned subsidiaries. Company’s subsidiaries and respective ownership percentage has not changed from the year ended December 31, 2022. These Financial Statements should be read in conjunction with the Company's audited financial statements for the year ended December 31, 2022, included in its Annual Report on Form 10-K, as filed with the SEC on March 30, 2023 (the "Annual Report"). On August 24, 2023, the Company effected a one-for-thirty reverse share split of its common shares ((the “Reverse Share Split”), effective as of 5:00 p.m. Eastern Time on August 24, 2023 (the “Effective Time”). All share and per share information in these financial statements has been retroactively adjusted to reflect the Reverse Share Split. No fractional shares were issued in connection with the Reverse Share Split. Instead, each fractional share remaining after completion of the Reverse Share Split that was less than half of a whole share was rounded down and canceled without consideration to the holders thereof and each fractional share that was at least half of a whole share was rounded up to one whole share. Discontinued Operations During the fiscal year 2022, the Company undertook various strategic initiatives aimed at reducing costs, improving organizational efficiency, and optimizing its business model. As part of these initiatives, the Company implemented several restructuring activities. Additionally, in December 2022, the Company made the decision to shut down its Portugal operations in order to preserve cash. In January 2023, the Company further approved the wind-down of its entire Portuguese operations to enhance operating margin and focus solely on cannabis cultivation and production in Colombia. As part of this restructuring plan, the Company has completed the cessation of its Portuguese flower cultivation, post-harvest processes, and manufacturing activities. Subsequently, the post harvest facility has been sold and preparations are currently underway for the sale of the farm land with the objective of concluding the sale by March 31, 2024. Considering the nature and extent of the restructuring activities undertaken, in accordance with Accounting Standards Codification (ASC) 205, Presentation of Financial Statements, the Company has determined that these operations meet the "discontinued operations" criteria as of September 30, 2023. As a result, the condensed consolidated statements of financial position, the condensed consolidated statements of operations, the condensed consolidated statements of cash flows, and the notes to the consolidated financial statements have been restated for all periods presented to reflect the discontinuation of these operations in accordance with ASC 205. Please refer to Note 19, "Discontinued Operations," for further details regarding the discontinued businesses. The discussion in the notes to these financial statements, unless otherwise noted, pertains solely to the Company's continuing operations. Going Concern These interim condensed financial statements have been prepared in accordance with U.S. GAAP, which assumes that the Company will be able to meet its obligations and continue its operations for the next twelve months from the date of issue. As shown in the accompanying interim condensed financial statements, the Company had an accumulated deficit as of September 30, 2023, as well as operating losses and negative cash flows from operations since inception and expects to continue to incur net losses for the foreseeable future until such time that it can generate significant revenue from the sale of its available inventories. At September 30, 2023, the Company had cash and cash equivalents of $6,472. As of September 30, 2023, the Company’s current working capital, anticipated operating expenses and net losses, and the uncertainties surrounding its ability to raise additional capital as needed, raise substantial doubt as to whether existing cash and cash equivalents will be sufficient to meet its obligations as they come due within twelve months from the date the consolidated financial statements were issued. The consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to execute its operating plans through 2023 and beyond depends on its ability to obtain additional funding, which may include several initiatives such as raising capital, reducing working capital, and monetizing non-core assets, to meet planned growth requirements and to fund future operations, which may not be available on acceptable terms, or at all. Principles of Consolidation The Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company's significant accounting policies are disclosed in its audited consolidated financial statements for the year ended December 31, 2022, included in the Annual Report. Except as noted below, there have been no other changes in the Company's significant accounting policies as discussed in the Annual Report. Use of Accounting Estimates The preparation of these Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the Financial Statements and accompanying notes in the reported period. These estimates include, but are not limited to, allowance for doubtful accounts, inventory valuation, determination of fair value of stock-based awards and estimate of incremental borrowing rate for determining the present value of future lease payments, intangible assets, useful lives of property and equipment, revenue recognition and income taxes and related tax asset valuation allowances. While the significant estimates made by management in the preparation of the consolidated financial statements are reasonable, prudent, and evaluated on an ongoing basis, actual results may differ materially from those estimates. Recently Adopted Accounting Pronouncements ASU No. 2016-13- Credit Losses on Financial Instruments (Topic 326) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses for certain financial instruments and financial assets. For trade receivables, we are required to estimate lifetime expected credit losses. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023. We have adopted the provisions of Accounting Standards Update (ASU) No. 2016-13, Credit Losses on Financial Instruments (Topic 326). After careful consideration and analysis, we have determined that the adoption of this pronouncement has not had a material impact on our financial reporting. Therefore, our financial statements and disclosures have not been significantly affected by the adoption of this standard.

FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FAIR VALUE MEASUREMENTS


	Level 1		Level 2		Level 3		Total

As of September 30, 2023
Assets:
Investment – Cansativa	—		—		1,896		1,896
Total Assets	$	—	$	—	$	1,896	$	1,896
Liabilities:
Loans and borrowings	—		1,336		—		1,336
Warrant liability	—		—		108		108

Total Liabilities	$	—	$	1,336	$	108	$	1,444

As of December 31, 2022
Assets:
Investment – Cansativa	—		—		5,679		5,679
Total Assets	$	—	$	—	$	5,679	$	5,679
Liabilities:
Loans and borrowings	—		1,530		—		1,530
Warrant liability	—		—		113		113
Total Liabilities	$	—	$	1,530	$	113	$	1,643

Investment – Cansativa

The following table provides a summary of changes in fair value of the Company’s level 3 investments for the nine months ended September 30, 2023:


	Level 3
Balance, December 31, 2022	$	5,679
Change in value due to foreign exchange gain	74
Balance, March 31, 2023	$	5,753

Change in value due to foreign exchange gain	24
Balance, June 30, 2023	$	5,777
Change in value due to foreign exchange loss	(176)
Impairment loss	(3,705)
Balance, September 30, 2023	$	1,896

During the nine months ended September 30, 2023, there were no transfers between fair value measurement levels.

The change in fair value of warrant liabilities related to private warrants during the nine months ended September 30, 2023, is as follows:


Private Placement Warrants:	Total Warrant Liability
Warrant liability at December 31, 2022	$	113
Change in fair value of warrant liability	44
Warrant liabilities at March 31, 2023	$	157
Change in fair value of warrant liability	11
Warrant liabilities at June 30, 2023	$	168
Change in fair value of warrant liability	(60)
Warrant liabilities at September 30, 2023	$	108


	As of
	September 30, 2023	December 31, 2022
Risk-free interest rate	4.98%	4.23%
Expected volatility	160%	105%
Share Price	$0.12	$0.31
Exercise Price	$11.50	$11.50
Expiration date	December 18, 2025	December 18, 2025

•The risk-free interest rate assumptions are based on U.S. dollar zero curve derived from swap rates at the valuation date, with a term to maturity matching the remaining term of warrants.

•The expected volatility assumptions are based on average of historical volatility based on comparable industry volatilities of public warrants.

•Exercise price and Share price at September 30, 2023 are adjusted post Reverse Share Split.

INVENTORIES, NET

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

INVENTORIES, NET

Inventories are comprised of the following items as of the periods presented:


	September 30, 2023		December 31, 2022
Raw materials	$	1,213	$	1,204
Work in progress – harvested cannabis and extracts	279		21
Finished goods – cannabis extracts	5,832		6,703
Finished goods – other	385		471
Total	$	7,709	$	8,399

PREPAID, DEPOSITS AND OTHER RECEIVABLES

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

PREPAID, DEPOSITS AND OTHER RECEIVABLES

Prepaid and advances are comprised of the following items as of the periods presented:


	September 30, 2023		December 31, 2022
Prepaid and advances	$	765	$	650
Indirect tax receivables	1,080		2,007
Deposits	96		51
Total	$	1,941	$	2,708

Prepaid and advances represents amounts paid upfront to vendors for director and officer's insurance and advances for supplies.

INVESTMENTS	9 Months Ended
INVESTMENTS	Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
INVESTMENTS	INVESTMENTS Cansativa On December 21, 2018, the Company, through its subsidiary Northern Swan , entered into a seed investment agreement with the existing stockholders of Cansativa GmbH (“Cansativa”), a German limited liability company primarily focused on the import and sale of cannabis products for medical use and related supplements and nutraceuticals. Prior to the Company’s investment, Cansativa’s registered and fully paid-in share capital amounted to 26,318 common shares. Under the investment agreement, the Company has agreed with the existing stockholders to invest up to EUR 7,000 in Cansativa in three separate tranches of, respectively, EUR 1,000, EUR 3,000 and up to a further EUR 3,000. The first EUR 1,000 (specifically, EUR 999.92, approximately $1,075, or “Seed Financing Round”) was invested in Cansativa to subscribe for 3,096 newly issued preferred voting shares at EUR 322.97 per preferred share, and as cash contributions from the Company to Cansativa. The seed EUR 322.97 per share price was based on a fully diluted pre-money valuation for Cansativa of EUR 8,500, and the increase of Cansativa’s registered share capital by the 3,096 preferred shares in the Seed Financing Round provided the Company with 10.53% of the total equity ownership of Cansativa. The Company paid the seed investment subscription by, first, an initial nominal payment of EUR 3.1, (i.e., EUR 1.00 per share) upon signing the investment agreement to demonstrate the Company’s intent to invest, and the remainder of EUR 996.82 was settled in January 2019 to officially close the investment deal after certain closing conditions have been met by the existing stockholders and Cansativa. The Company accounted for its investment in Cansativa using the equity accounting method, due to the Company's significant influence, in accordance with ASC 323, Investments — Equity Method and Joint Ventures. The Company recorded its investment in Cansativa at the cost basis of an aggregated amount of EUR 999.92, approximately $1,075, which is comprised of EUR 3.10 for the initial nominal amount of the Seed Financing Round and EUR 996.82 for the remaining Seed Financing Round (i.e., Capital Reserve Payment), with no transaction costs. In accordance with the seed investment agreement, in September 2019, the Company made an additional investment of approximately EUR 650, or approximately $722, for 2,138 shares in Cansativa, thereby increasing its equity ownership to 16.6% of the book value of Cansativa’s net assets of approximately EUR 1,233, and approximately EUR 1,122 of equity method goodwill as Cansativa was still in the process of getting the licenses and expanding its operations. As of September 30, 2020, the balance of Tranche 2 option expired un-exercised and as a result the Company recognized a loss on investment of approximately $370 in its Statement of Operations and Comprehensive Loss and the carrying value of the Tranche 2 option was reduced to nil. In December 2020, Cansativa allocated shares of its common stock to a newly installed employee-stock ownership plan (“ESOP”). As a result of the ESOP installment, the Company’s equity ownership of Cansativa, on a fully-diluted basis, decreased from 16.59% to 15.80% of the book value of Cansativa’s net assets. Additionally, Cansativa raised additional capital through the issuance of Series A preferred stock (“Cansativa Series A Shares”) to a third-party investor at a per share price of EUR 543.31. As a result of the Series A Share issuance, the Company’s equity ownership of Cansativa, on a fully diluted basis, decreased from 15.80% to 14.22% of the book value of Cansativa’s net assets. The Company accounted for the transaction as a proportionate sale of ownership share and recognized a gain of approximately $211 in its consolidated statement of operations within loss on investments line. This change did not impact the equity method classification. In April 2022, the Company sold 1,586 shares in Cansativa to an unrelated third-party for approximately EUR 2,300. Additionally Cansativa issued 10,184 series B and 992 ESOP shares. As a result, the Company's equity ownership of Cansativa, on a fully diluted basis, decreased from 14.22% to 7.6% of the book value of Cansativa's net assets. Furthermore, the Company relinquished the board seat, indicating that the Company's influence was no longer "significant", to which the equity method of accounting was applicable. The Company started to account for this investment under ASC 321, Investments – Equity Securities. The Company utilized the practical expedient under ASC 321 as the investment does not qualify for the practical expedient under ASC 820 and there is no readily determinable fair value for these privately held shares of Cansativa on a recurring basis. At the time of the sale, the Company compared the transaction value of the shares sold to the carrying value of shares sold and recognized a gain of $1,983. Immediately following the sale, the Company then remeasured its retained interest which resulted in an additional gain of $4,868. A total of $6,851 is recorded as gain on investment during the nine months period ended September 30, 2022. On October 17, 2023, Northern Swan entered into an agreement to sell a total of 3,648 shares of Cansativa to Cansativa and EIP Entrepreneurial Investment GmbH, representing Northern Swan’s entire interest in Cansativa, for approximately EUR 1.8 million ($1.9 million). The Company compared the subsequent transaction value of the shares sold to the carrying value and the impairment loss of $3,705 was recorded in the Consolidated statement of Operations during the three and nine months ended September 30, 2023.

INTANGIBLE ASSETS, NET

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS, NET

INTANGIBLE ASSETS, NETAs part of the Herbal Brand acquisition in 2019, the Company acquired finite-lived intangible assets with a gross value of approximately $7,091. During the three months ended September 30, 2023 and 2022 the Company recorded $167 and $191, respectively, of amortization related to its finite-lived intangible assets. During the nine months ended September 30, 2023 and 2022 the Company recorded $533 and $573, respectively, of amortization related to its finite-lived intangible assets.The following tables present details of the Company’s total intangible assets as of September 30, 2023 and December 31, 2022. The value of product formulation intangible asset is included in the value of Brand:


	September 30, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		767		233		2.6
Customer list	650		574		76		0.6
Trade name	4,516		2,004		2,512		5.6
Total finite-lived intangible assets	$	7,091	$	4,270	$	2,821


	December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		669		331		3.0
Customer list	650		478		172		1.3
Trade name	4,516		1,665		2,851		6.3
Total finite-lived intangible assets	$	7,091	$	3,737	$	3,354

Indefinite-lived intangible assets:
Licenses	$	19,000	N/A		$	19,000
Impairment Charge	(19,000)		N/A		(19,000)
Total indefinite-lived intangible assets	—				—

Total intangible assets	$	7,091	$	3,737	$	3,354

Annual Impairment Testing

In accordance with ASC Topic 350, “Intangibles – Goodwill and Other,” the Company performs its annual impairment test as

management assesses whether any indicators of impairment exist requiring the Company to perform an interim goodwill and other intangible assets impairment analysis.

Impairment Testing - Finite-Lived Intangibles

Impairment Testing - Indefinite-Lived Intangibles

Amortization Expense

The following table reflects the estimated future amortization expense for each period presented for the Company’s finite-lived intangible assets as of September 30, 2023:


	Estimated Amortization Expense
2023	$	167
2024	585
2025	542
2026	482
2027	452
Thereafter	593
Total	$	2,821

PROPERTY, PLANT AND EQUIPMENT, NET

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT, NET

Property, plant and equipment, net consisted of the following:


	September 30, 2023		December 31, 2022
Land	$	1,806	$	1,806
Building & warehouse	7,768		7,658
Laboratory equipment	6,496		6,416
Agricultural equipment	1,480		1,477
Computer equipment	1,433		1,397
Furniture & appliances	794		785
Construction in progress	106		240
Other	1,258		1,304
Property, plant and equipment, gross	21,141		21,083
Less: accumulated depreciation	(8,389)		(7,120)
Property, plant and equipment, net	$	12,752	$	13,963

DEBT

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

DEBT


	September 30, 2023		December 31, 2022
Loans and borrowings, current portion	$	477	$	465
Loans and borrowings, non-current portion	859		1,065
Total debt	$	1,336	$	1,530

Portugal Debt

Colombia Debt

CAPITAL STOCK	9 Months Ended
CAPITAL STOCK	Sep. 30, 2023
Equity [Abstract]
CAPITAL STOCK	CAPITAL STOCK Common Shares As of September 30, 2023 and December 31, 2022, a total of 1,726,145 and 1,454,559 common shares were issued and outstanding, respectively. For more information, refer to Note 2. The increase in outstanding shares was primarily the result of shares issued under the ATM. See Equity Distribution Agreement disclosed below. Reverse Share Split On August 24, 2023, the Company effected a one-for-thirty Reverse Share Split of its common shares All share and per share information in these financial statements has been retroactively adjusted to reflect the Reverse Share Split. No fractional shares were issued in connection with the Reverse Share Split. Instead, each fractional share remaining after completion of the Reverse Share Split that was less than half of a whole share was rounded down and canceled without consideration to the holders thereof and each fractional share that was at least half of a whole share was rounded up to one whole share. As a result of the Reverse Share Split, at the Effective Time, the number of outstanding Shares was reduced from approximately 45.7 million to approximately 1.5 million. The Reverse Share Split was, effected to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company to maintain a minimum bid price of at least $1.00 per share. For the three months ended September 30, 2023, the Company issued and sold 201,912 shares on a post-Reverse Share Split basis pursuant to the ATM offering, for aggregate net proceeds of $824 which consisted of gross proceeds of $902 and $78 of equity issuance costs. For the nine months ended September 30, 2023, the Company issued and sold 253,898 shares on a post-Reverse Share Split basis pursuant to the ATM offering, for aggregate net proceeds of $1,140 which consisted of gross proceeds of $1,340 and $200 of equity issuance costs. Equity Distribution Agreement On January 14, 2022, the Company entered into an Equity Distribution Agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC, as sales agent (the “Agent”). Under the terms of the Equity Distribution Agreement, the Company may issue and sell its common shares, without par value, having an aggregate offering price of up to $50,000 from time to time through the Agent. The issuance and sale of the common shares under the Equity Distribution Agreement have been made, and any such future sales will be made, pursuant to the Company’s effective registration statement on Form S-3 (File No. 333-262183), which includes an “at-the-market” (“ATM”) offering prospectus supplement (the "Prospectus Supplement"), as amended from time to time. Following the filing of the 2022 Form 10-K, we are subject to the limitations under General Instruction I.B.6. of Form S-3. and , we filed Amendment No. 3 to the Prospectus Supplement, to reflect the lower maximum offering amount based on the then aggregate market value of our outstanding common shares held by non-affiliates. If our public float increases such that we may sell additional amounts under the Equity Distribution Agreement and the Prospectus Supplement, we will file another amendment to the Prospectus Supplement prior to making additional sales. Warrants As of September 30, 2023, the Company had 12,877,361 of its public warrants classified as a component of equity and 4,900,000 of its private warrants recognized as liability. In connection with the Reverse Share Split, the warrants were adjusted in accordance with their terms such that each warrant entitles the holder to purchase 1/30 common share, at an exercise price of $345 per share. The warrants will expire on December 18, 2025, at 5:00 p.m., New York City time, or earlier upon redemption. The Company may redeem the outstanding public warrants at a price of $0.01 per warrant if the last reported sales price of the Company’s common shares equals or exceeds $540.00 per share (as adjusted for share splits, share capitalization, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 trading day period ending on the third trading day prior to the date on which the Company will send the notice of redemption to the warrant holders. The private warrants were issued in the same form as the public warrants, but they (i) are not redeemable by the Company and (ii) may be exercised for cash or on a cashless basis at the holder’s option, in either case as long as they are held by the initial purchasers or their permitted transferees (as defined in the warrant agreement). Once a private warrant is transferred to a holder other than an affiliate or permitted transferee, it is treated as a public warrant for all purposes. The terms of the warrants may be amended in a manner that may be adverse to holders with the approval of the holders of at least a majority 50.1% of the then outstanding warrants. In accordance to ASC 815, certain provisions of private warrants that do not meet the criteria for equity treatment are recorded as liabilities with the offset to additional paid-in capital and are measured at fair value at inception and at each reporting period in accordance with ASC 820, Fair Value Measurement, with changes in fair value recognized in the statement of operations and comprehensive loss in the period of change. As of September 30, 2023, the Company performed a valuation of the private warrants and as a result recorded a net loss on remeasurement for the three and nine months ended September 30, 2023, of approximately $60 and $5, respectively, in its statement of operations. As of September 30, 2022, the Company performed a valuation of the private warrants and as a result recorded, in the statement of operations, a net gain on remeasurement for the three and nine months ended September 30, 2022 of approximately $196 and $2,009, respectively.

GENERAL AND ADMINISTRATION

9 Months Ended

Sep. 30, 2023

General and Administrative Expense [Abstract]

GENERAL AND ADMINISTRATION

The components of general and administrative expenses were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Salaries and benefits	$	2,263	$	2,781	$	7,464	$	9,719
Office and administration	736		1,096		2,168		3,169
Professional fees	667		495		2,933		2,893
Share based compensation	52		958		954		2,606
Rent	178		196		564		627
Other (a)	259		(84)		244		(149)
Total	$	4,155	$	5,442	$	14,327	$	18,865

RESTRUCTURING EXPENSE	9 Months Ended
RESTRUCTURING EXPENSE	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
RESTRUCTURING EXPENSE	RESTRUCTURING EXPENSEThe Company has been reviewing, planning and implementing various strategic initiatives targeted principally at reducing costs, enhancing organizational efficiency and optimizing its business model. As part of this process, the Company recorded a restructuring charge related to asset write off, severance, and other related costs during the year 2022. For the nine months ended September 30, 2022, the Company recorded $3,761 of restructuring charge related to asset write off, severance, and other related costs. No such restructuring expense was charged during the nine months ended September 30, 2023.Our restructuring charges are comprised primarily of costs related to asset abandonment, including future lease commitments, and employee termination costs related to headcount reductions.

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

Stock-Based Compensation Plans

The Company's 2018 Equity Incentive Plan, 2020 Equity Incentive Plan and Earnout Plan are described in the Company's 2022 Form 10-K.

Share-Based Compensation Expense


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Share-based compensation award type:
Stock Options	$	7	$	66	$	820	$	336
RSUs	45		892		134		2,270
Total Shared Based Compensation Expense	$	52	$	958	$	954	$	2,606

The Company recognized share-based compensation expense in general and administrative expense.

Stock Options

The following table is a summary of options activity for the Company’s equity incentive plans for the nine months ended September 30, 2023:


	Stock Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance as at December 31, 2022	13,619	$	233.46	2.56	$	—


Forfeited	(479)	$	336.36	—	—
Expired	(4,222)	$	320.87	—	—
Balance as of September 30, 2023	8,918	$	157.03	1.52	$	—
Vested and expected to vest as of September 30, 2023	8,576	$	151.33	1.56	$	—
Vested and exercisable as of September 30, 2023	7,731	$	123.73	1.04	$	—

of 0.95 and 1.0 years respectively.

Restricted Share Units

Time-based Restricted Share Units

The fair value for time-based RSUs is based on the closing price of the Company’s common shares on the grant date.

The following table summarizes the changes in the Company’s time-based restricted share unit activity during the nine months ended September 30, 2023:


	Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested as of December 31, 2022	45,566	$	105.05
Granted	45,251	7.49
Vested	(18,108)	88.96
Canceled/forfeited	(5,602)	43.38
Non-vested as of September 30, 2023	67,107	$	48.75

Market-based Restricted Share Units

The following table summarizes the changes in the Company’s market-based restricted share unit activity during the nine months ended September 30, 2023:


	Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested as of December 31, 2022	17,632	$	384.03
Granted	—	—
Vested	(15)	274.52
Expired	(71)	272.58
Forfeited	(3,874)	393.29
Non-vested as of September 30, 2023	13,672	$	382.11

REVENUE	9 Months Ended
REVENUE	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUEThe Company’s policy is to recognize revenue at an amount that reflects the consideration that the Company expects that it will be entitled to receive in exchange for transferring goods or services to its customers. The Company’s policy is to record revenue when control of the goods transfers to the customer. The Company evaluates the transfer of control through evidence of the customer’s receipt and acceptance, transfer of title, the Company’s right to payment for those products and the customer’s ability to direct the use of those products upon receipt. Typically, the Company’s performance obligations are satisfied at a point in time, and revenue is recognized, either upon shipment or delivery of goods. In instances where control transfers upon customer acceptance, the Company estimates the time period it takes for the customer to take possession and the Company recognizes revenue based on such estimates. The transaction price is typically based on the amount billed to the customer and includes estimated variable consideration where applicable. Disaggregation of Revenue Refer to Note 16 Segment Reporting to our unaudited condensed consolidated interim financial statements for the period ended September 30, 2023 included in this Form 10-Q for disaggregation of revenue data. Contract Balances The timing of revenue recognition, billing and cash collections results in billed accounts receivable and deferred revenue primarily attributable to advanced customer payment, on the Consolidated Statements of Financial Position. Accounts receivables are recognized in the period in which the Company's right to the consideration is unconditional. The Company's contract liabilities consist of advance payment from a customer, which is classified on the Consolidated Statements of Financial Position as current and non-current deferred revenue. As of September 30, 2023, the Company's deferred revenue, included in current and non-current liabilities was $437 and $nil, respectively. As of December 31, 2022, the Company's deferred revenue, included in current and non-current liabilities was $1,072 and $nil, respectively.

SEGMENT REPORTING

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

SEGMENT REPORTING

As of September 30, 2023, the Company’s operations were organized in the following two reportable segments:

The following table is a comparative summary of the Company’s net sales and segment profit by reportable segment for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022 (*)		2023		2022 (*)
Segment Net Sales:
Cannabinoid	$	1,442	$	613	$	4,537	$	3,166
Non-Cannabinoid	2,378		2,254		8,242		8,842
Total net sales	3,820		2,867		12,779		12,008

Segment Profit (Loss):
Cannabinoid	(2,225)		(2,732)		(6,237)		(11,144)
Non-Cannabinoid	316		95		1,594		1,109
Total segment loss	$	(1,909)	$	(2,637)	$	(4,643)	$	(10,035)

Reconciliation:
Total segment loss	(1,909)		(2,637)		(4,643)		(10,035)
Unallocated corporate expenses	(1,706)		(1,424)		(5,835)		(6,801)
Non-cash share-based compensation	(52)		(958)		(954)		(2,606)
Depreciation and amortization	290		(305)		750		(950)

Goodwill impairment	—		(19,000)		—		(19,000)
Loss from continuing operations before income taxes	$	(3,377)	$	(24,324)	$	(10,682)	$	(39,392)

Loss on debt extinguishment, net	—		—		—		2,263

Gain on remeasurement of warrant liability	(60)		(196)		(5)		(2,009)
Gain on investment	—		—		—		(6,851)
Impairment investment	3,705		—		3,705		—
Foreign exchange loss	275		669		297		1,144
Interest and amortization of debt issuance cost	5		(58)		23		2,696
Other (income) expense, net	(31)		102		(19)		111
Income (loss) before loss from equity investment	$	(7,271)	$	(24,841)	$	(14,683)	$	(36,746)

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

The following table disaggregates the Company’s revenue by channel for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Mass retail	$	2,618	$	1,570	$	8,133	$	6,065
Distributors	923		927		3,738		4,250
Specialty, health and other retail	107		282		361		1,234
E-commerce	172		88		547		459
Total	$	3,820	$	2,867	$	12,779	$	12,008

The following table represents the Company's revenues attributed to countries based on location of customer:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
United States	$	2,378	$	2,228	$	8,242	$	8,736
Israel	—		$	—	$	600	$	704
Australia	685		77		1,392		445
Brazil	507		249		1,778		1,169
Germany	59		275		68		722
Other	191		38		699		232
Total	$	3,820	$	2,867	$	12,779	$	12,008

Percentage of Revenues

Percentage of Accounts Receivable

Three Months Ended September 30,

Nine Months Ended September 30,

September 30,

December 31,

2023

2022

2023

2022

2023

2022

Customer A (a)

10%

20%

12%

13%

18%

Customer B (b)

20%

13%

Customer C (b)

11%

Customer D (b)

15%

Customer E (b)

13%

15%

10%

Customer F (b)

16%

Customer G (b)

13%

* denotes less than 10%

(a) net sales attributed are reflected in the non-cannabinoid segments

(b) net sales attributed are reflected in the cannabinoid segments

The following table disaggregates the Company’s long-lived assets, by segment for the periods presented:


	September 30, 2023		December 31, 2022
Long-lived assets
Cannabinoid	$	14,163	$	15,308
Non-Cannabinoid	89		155
Total	$	14,252	$	15,463

Long-lived assets consist of non-current assets other than goodwill; intangible assets, net; investments in unconsolidated subsidiaries and equity securities; and financial instruments.

NET INCOME (LOSS) PER SHARE

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Loss from continuing operations	$	(7,271)	$	(18,191)	$	(14,683)	(30,160)
Income (loss) from discontinued operations	$	2,133	$	(1,972)	$	1,869	(7,189)
Net loss - basic and diluted	$	(5,138)	$	(20,163)	$	(12,814)	$	(37,349)





Denominator:
Weighted-average common shares outstanding - basic and diluted	1,580,456		1,407,419		1,513,575		1,221,107

Net loss per common share - basic and diluted:
Loss from continuing operations	$	(4.60)	$	(12.93)	$	(9.70)	$	(24.70)
Income (loss) from discontinued operations	$	1.35	$	(1.41)	$	1.23	$	(5.90)



	September 30, 2023	September 30, 2022
		(a)
SAMA earnout shares	19,007	19,007
Stock options	8,918	14,530
Unvested restricted share units	80,779	77,128
Total	108,704	110,665
Common Stock Warrants (b)	17,777,361	17,840,951

(a) Prior year numbers are adjusted for the Reverse Share Split.

LEASES

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

LEASES

Practical Expedients


	Financial Statement Classification	Three Months Ended September 30, 2023		Nine Months Ended September 30, 2023
Operating lease costs:
Fixed lease costs	Operating expenses	$	171	$	530
Total lease costs		$	171	$	530

The following table shows our undiscounted future fixed payment obligations under our recognized operating leases and a reconciliation to the operating lease liabilities as of September 30, 2023:


Leases and a reconciliation to the operating lease liabilities as of September 30, 2023
Remainder of Year 2023	$	183
2024	370
2025	107
2026	114
2027	113
Thereafter	84
Total future fixed operating lease payments	$	971

Less: Imputed interest	$	93
Total operating lease liabilities	$	878

Weighted-average remaining lease term - operating leases	2.89
Weighted-average discount rate - operating leases	8.0		%

DISCONTINUED OPERATIONS

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

DISCONTINUED OPERATIONS


		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Revenue, net		$	—	$	438	$	551	$	1,178



Cost of sales		—		(1,456)		—		(3,929)
Gross profit (loss)		—		(1,018)		551		(2,751)
Expenses
General and administrative		584		645		1,430		3,496
Restructuring expenses		—				—		30
Depreciation and amortization		—		203		—		613
Total expenses		584		848		1,430		4,139

Loss from operations		(584)		(1,866)		(879)		(6,890)

Interest (income) expense		14		7		33		24
Gain on sale of assets	—	(2,778)		—		(2,825)
Foreign exchange loss		48		99		44		275
Other income, net		(1)		—		—		—

Net gain (loss)		$	2,133	$	(1,972)	$	1,869	$	(7,189)

COMMITMENT AND CONTINGENCIES	9 Months Ended
COMMITMENT AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENT AND CONTINGENCIES	COMMITMENT AND CONTINGENCIESOn July 1, 2023, an asset purchase agreement (the “APA”) was entered into by and among (the Company) as guarantor, Clever Leaves Portugal Unipessoal, Lda. (the “Seller” or “Clever Leaves Portugal”), a wholly-owned subsidiary of the Company, and Terra Verde, Lda. (the “Purchaser”), a wholly-owned subsidiary of Curaleaf International, part of Curaleaf Holdings, Inc. Pursuant to the APA, the Purchaser agreed to acquire, and the Seller agreed to sell, certain laboratory and processing equipment for the production of cannabinoid products, as well as informational rights to policies and procedures for the production and manufacture of such cannabinoids that the Seller used in its EU-GMP certified cannabis processing facility in Setubal, Portugal. Under the terms of the APA, the Company has provided a guarantee in case of malfunctioning of the equipment for a period of 12 months expiring July 2024. The total amount of the guarantee will not exceed, in any circumstances, €500 and undertakes the obligation of principal payor renouncing to the benefit of prior foreclosure of the Seller’s assets. The Company considers the probability of requiring payment under the guarantee to be remote. Hence, no liabilities or expenses are recorded in the financial statements.

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS Agreement to sell Investment in Cansativa On October 17, 2023, Northern Swan, a wholly-owned subsidiary of (the Company), entered into the First Share Purchase and Transfer Agreement (the “SPA”) by and among Northern Swan, as seller, and Cansativa GmbH (“Cansativa”) and EIP Entrepreneurial Investment GmbH (“EIP”), as buyers. Pursuant to the SPA, Northern Swan agreed to sell a total of 3,648 shares of Cansativa, representing its entire interest in Cansativa, of which 3,582 shares were purchased by Cansativa and 66 shares were purchased by EIP, for a total purchase price of approximately €1.8 million ($1.9 million). The Company received the funds in November, 2023.

BASIS OF PRESENTATION (Policies)	9 Months Ended
BASIS OF PRESENTATION (Policies)	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Discontinued Operations	Considering the nature and extent of the restructuring activities undertaken, in accordance with Accounting Standards Codification (ASC) 205, Presentation of Financial Statements, the Company has determined that these operations meet the "discontinued operations" criteria as of September 30, 2023. As a result, the condensed consolidated statements of financial position, the condensed consolidated statements of operations, the condensed consolidated statements of cash flows, and the notes to the consolidated financial statements have been restated for all periods presented to reflect the discontinuation of these operations in accordance with ASC 205.
Principles of Consolidation	Principles of Consolidation The Financial Statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Use of Accounting Estimates	Use of Accounting EstimatesThe preparation of these Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the Financial Statements and accompanying notes in the reported period. These estimates include, but are not limited to, allowance for doubtful accounts, inventory valuation, determination of fair value of stock-based awards and estimate of incremental borrowing rate for determining the present value of future lease payments, intangible assets, useful lives of property and equipment, revenue recognition and income taxes and related tax asset valuation allowances. While the significant estimates made by management in the preparation of the consolidated financial statements are reasonable, prudent, and evaluated on an ongoing basis, actual results may differ materially from those estimates.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements ASU No. 2016-13- Credit Losses on Financial Instruments (Topic 326) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 replaces the existing incurred loss impairment model with a forward-looking expected credit loss model which will result in earlier recognition of credit losses for certain financial instruments and financial assets. For trade receivables, we are required to estimate lifetime expected credit losses. ASU 2016-13 is effective for the Company’s fiscal year beginning January 1, 2023. We have adopted the provisions of Accounting Standards Update (ASU) No. 2016-13, Credit Losses on Financial Instruments (Topic 326). After careful consideration and analysis, we have determined that the adoption of this pronouncement has not had a material impact on our financial reporting. Therefore, our financial statements and disclosures have not been significantly affected by the adoption of this standard.

FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis


	Level 1		Level 2		Level 3		Total

As of September 30, 2023
Assets:
Investment – Cansativa	—		—		1,896		1,896
Total Assets	$	—	$	—	$	1,896	$	1,896
Liabilities:
Loans and borrowings	—		1,336		—		1,336
Warrant liability	—		—		108		108

Total Liabilities	$	—	$	1,336	$	108	$	1,444

As of December 31, 2022
Assets:
Investment – Cansativa	—		—		5,679		5,679
Total Assets	$	—	$	—	$	5,679	$	5,679
Liabilities:
Loans and borrowings	—		1,530		—		1,530
Warrant liability	—		—		113		113
Total Liabilities	$	—	$	1,530	$	113	$	1,643

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The following table provides a summary of changes in fair value of the Company’s level 3 investments for the nine months ended September 30, 2023:


	Level 3
Balance, December 31, 2022	$	5,679
Change in value due to foreign exchange gain	74
Balance, March 31, 2023	$	5,753

Change in value due to foreign exchange gain	24
Balance, June 30, 2023	$	5,777
Change in value due to foreign exchange loss	(176)
Impairment loss	(3,705)
Balance, September 30, 2023	$	1,896

Schedule of Changes in the Fair Value of Warrant Liabilities

The change in fair value of warrant liabilities related to private warrants during the nine months ended September 30, 2023, is as follows:


Private Placement Warrants:	Total Warrant Liability
Warrant liability at December 31, 2022	$	113
Change in fair value of warrant liability	44
Warrant liabilities at March 31, 2023	$	157
Change in fair value of warrant liability	11
Warrant liabilities at June 30, 2023	$	168
Change in fair value of warrant liability	(60)
Warrant liabilities at September 30, 2023	$	108

Schedule of Fair Value Measurement Inputs and Valuation Techniques


	As of
	September 30, 2023	December 31, 2022
Risk-free interest rate	4.98%	4.23%
Expected volatility	160%	105%
Share Price	$0.12	$0.31
Exercise Price	$11.50	$11.50
Expiration date	December 18, 2025	December 18, 2025

INVENTORIES, NET (Tables)

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are comprised of the following items as of the periods presented:


	September 30, 2023		December 31, 2022
Raw materials	$	1,213	$	1,204
Work in progress – harvested cannabis and extracts	279		21
Finished goods – cannabis extracts	5,832		6,703
Finished goods – other	385		471
Total	$	7,709	$	8,399

PREPAID, DEPOSITS AND OTHER RECEIVABLES (Tables)

9 Months Ended

Sep. 30, 2023

Payables and Accruals [Abstract]

Schedule of Prepaids and Advances

Prepaid and advances are comprised of the following items as of the periods presented:


	September 30, 2023		December 31, 2022
Prepaid and advances	$	765	$	650
Indirect tax receivables	1,080		2,007
Deposits	96		51
Total	$	1,941	$	2,708

INTANGIBLE ASSETS, NET (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Indefinite-Lived Intangible Assets

The following tables present details of the Company’s total intangible assets as of September 30, 2023 and December 31, 2022. The value of product formulation intangible asset is included in the value of Brand:


	September 30, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		767		233		2.6
Customer list	650		574		76		0.6
Trade name	4,516		2,004		2,512		5.6
Total finite-lived intangible assets	$	7,091	$	4,270	$	2,821


	December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		669		331		3.0
Customer list	650		478		172		1.3
Trade name	4,516		1,665		2,851		6.3
Total finite-lived intangible assets	$	7,091	$	3,737	$	3,354

Indefinite-lived intangible assets:
Licenses	$	19,000	N/A		$	19,000
Impairment Charge	(19,000)		N/A		(19,000)
Total indefinite-lived intangible assets	—				—

Total intangible assets	$	7,091	$	3,737	$	3,354

Schedule of Finite-Lived Intangible Assets


	September 30, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		767		233		2.6
Customer list	650		574		76		0.6
Trade name	4,516		2,004		2,512		5.6
Total finite-lived intangible assets	$	7,091	$	4,270	$	2,821


	December 31, 2022
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Weighted- Average Useful Life (in Years)
Finite-lived intangible assets:
Customer contracts	$	925	$	925	$	—	0.0
Customer relationships	1,000		669		331		3.0
Customer list	650		478		172		1.3
Trade name	4,516		1,665		2,851		6.3
Total finite-lived intangible assets	$	7,091	$	3,737	$	3,354

Indefinite-lived intangible assets:
Licenses	$	19,000	N/A		$	19,000
Impairment Charge	(19,000)		N/A		(19,000)
Total indefinite-lived intangible assets	—				—

Total intangible assets	$	7,091	$	3,737	$	3,354

Schedule of Finite-lived Intangible Assets Amortization Expense

The following table reflects the estimated future amortization expense for each period presented for the Company’s finite-lived intangible assets as of September 30, 2023:


	Estimated Amortization Expense
2023	$	167
2024	585
2025	542
2026	482
2027	452
Thereafter	593
Total	$	2,821

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment, net consisted of the following:


	September 30, 2023		December 31, 2022
Land	$	1,806	$	1,806
Building & warehouse	7,768		7,658
Laboratory equipment	6,496		6,416
Agricultural equipment	1,480		1,477
Computer equipment	1,433		1,397
Furniture & appliances	794		785
Construction in progress	106		240
Other	1,258		1,304
Property, plant and equipment, gross	21,141		21,083
Less: accumulated depreciation	(8,389)		(7,120)
Property, plant and equipment, net	$	12,752	$	13,963

DEBT (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Debt


	September 30, 2023		December 31, 2022
Loans and borrowings, current portion	$	477	$	465
Loans and borrowings, non-current portion	859		1,065
Total debt	$	1,336	$	1,530

GENERAL AND ADMINISTRATION (Tables)

9 Months Ended

Sep. 30, 2023

General and Administrative Expense [Abstract]

Schedule of General and Administrative Expenses

The components of general and administrative expenses were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Salaries and benefits	$	2,263	$	2,781	$	7,464	$	9,719
Office and administration	736		1,096		2,168		3,169
Professional fees	667		495		2,933		2,893
Share based compensation	52		958		954		2,606
Rent	178		196		564		627
Other (a)	259		(84)		244		(149)
Total	$	4,155	$	5,442	$	14,327	$	18,865

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Share-Based Compensation Expense


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

Share-based compensation award type:
Stock Options	$	7	$	66	$	820	$	336
RSUs	45		892		134		2,270
Total Shared Based Compensation Expense	$	52	$	958	$	954	$	2,606

Schedule of Share-based Payment Arrangement, Option, Activity

The following table is a summary of options activity for the Company’s equity incentive plans for the nine months ended September 30, 2023:


	Stock Options	Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value
Balance as at December 31, 2022	13,619	$	233.46	2.56	$	—


Forfeited	(479)	$	336.36	—	—
Expired	(4,222)	$	320.87	—	—
Balance as of September 30, 2023	8,918	$	157.03	1.52	$	—
Vested and expected to vest as of September 30, 2023	8,576	$	151.33	1.56	$	—
Vested and exercisable as of September 30, 2023	7,731	$	123.73	1.04	$	—

Schedule of Unvested Restricted Stock Units Roll Forward

The following table summarizes the changes in the Company’s time-based restricted share unit activity during the nine months ended September 30, 2023:


	Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested as of December 31, 2022	45,566	$	105.05
Granted	45,251	7.49
Vested	(18,108)	88.96
Canceled/forfeited	(5,602)	43.38
Non-vested as of September 30, 2023	67,107	$	48.75

The following table summarizes the changes in the Company’s market-based restricted share unit activity during the nine months ended September 30, 2023:


	Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested as of December 31, 2022	17,632	$	384.03
Granted	—	—
Vested	(15)	274.52
Expired	(71)	272.58
Forfeited	(3,874)	393.29
Non-vested as of September 30, 2023	13,672	$	382.11

SEGMENT REPORTING (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

The following table is a comparative summary of the Company’s net sales and segment profit by reportable segment for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022 (*)		2023		2022 (*)
Segment Net Sales:
Cannabinoid	$	1,442	$	613	$	4,537	$	3,166
Non-Cannabinoid	2,378		2,254		8,242		8,842
Total net sales	3,820		2,867		12,779		12,008

Segment Profit (Loss):
Cannabinoid	(2,225)		(2,732)		(6,237)		(11,144)
Non-Cannabinoid	316		95		1,594		1,109
Total segment loss	$	(1,909)	$	(2,637)	$	(4,643)	$	(10,035)

Reconciliation:
Total segment loss	(1,909)		(2,637)		(4,643)		(10,035)
Unallocated corporate expenses	(1,706)		(1,424)		(5,835)		(6,801)
Non-cash share-based compensation	(52)		(958)		(954)		(2,606)
Depreciation and amortization	290		(305)		750		(950)

Goodwill impairment	—		(19,000)		—		(19,000)
Loss from continuing operations before income taxes	$	(3,377)	$	(24,324)	$	(10,682)	$	(39,392)

Loss on debt extinguishment, net	—		—		—		2,263

Gain on remeasurement of warrant liability	(60)		(196)		(5)		(2,009)
Gain on investment	—		—		—		(6,851)
Impairment investment	3,705		—		3,705		—
Foreign exchange loss	275		669		297		1,144
Interest and amortization of debt issuance cost	5		(58)		23		2,696
Other (income) expense, net	(31)		102		(19)		111
Income (loss) before loss from equity investment	$	(7,271)	$	(24,841)	$	(14,683)	$	(36,746)

(*)Prior period numbers are re-stated to exclude discontinued operations to make it comparative with current period numbers.

Schedule of Disaggregation of Revenue

The following table disaggregates the Company’s revenue by channel for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Mass retail	$	2,618	$	1,570	$	8,133	$	6,065
Distributors	923		927		3,738		4,250
Specialty, health and other retail	107		282		361		1,234
E-commerce	172		88		547		459
Total	$	3,820	$	2,867	$	12,779	$	12,008

The following table represents the Company's revenues attributed to countries based on location of customer:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
United States	$	2,378	$	2,228	$	8,242	$	8,736
Israel	—		$	—	$	600	$	704
Australia	685		77		1,392		445
Brazil	507		249		1,778		1,169
Germany	59		275		68		722
Other	191		38		699		232
Total	$	3,820	$	2,867	$	12,779	$	12,008

Schedule of Revenue by Major Customers by Reporting Segments

Percentage of Revenues

Percentage of Accounts Receivable

Three Months Ended September 30,

Nine Months Ended September 30,

September 30,

December 31,

2023

2022

2023

2022

2023

2022

Customer A (a)

10%

20%

12%

13%

18%

Customer B (b)

20%

13%

Customer C (b)

11%

Customer D (b)

15%

Customer E (b)

13%

15%

10%

Customer F (b)

16%

Customer G (b)

13%

* denotes less than 10%

(a) net sales attributed are reflected in the non-cannabinoid segments

(b) net sales attributed are reflected in the cannabinoid segments

Schedule of Long-lived Assets by Geographic Areas

The following table disaggregates the Company’s long-lived assets, by segment for the periods presented:


	September 30, 2023		December 31, 2022
Long-lived assets
Cannabinoid	$	14,163	$	15,308
Non-Cannabinoid	89		155
Total	$	14,252	$	15,463

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Loss Per Share, Basic and Diluted

The following table sets forth the computation of basic and diluted net loss and the weighted average number of shares used in computing basic and diluted net loss per share:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Numerator:
Loss from continuing operations	$	(7,271)	$	(18,191)	$	(14,683)	(30,160)
Income (loss) from discontinued operations	$	2,133	$	(1,972)	$	1,869	(7,189)
Net loss - basic and diluted	$	(5,138)	$	(20,163)	$	(12,814)	$	(37,349)





Denominator:
Weighted-average common shares outstanding - basic and diluted	1,580,456		1,407,419		1,513,575		1,221,107

Net loss per common share - basic and diluted:
Loss from continuing operations	$	(4.60)	$	(12.93)	$	(9.70)	$	(24.70)
Income (loss) from discontinued operations	$	1.35	$	(1.41)	$	1.23	$	(5.90)

Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share



	September 30, 2023	September 30, 2022
		(a)
SAMA earnout shares	19,007	19,007
Stock options	8,918	14,530
Unvested restricted share units	80,779	77,128
Total	108,704	110,665
Common Stock Warrants (b)	17,777,361	17,840,951

(a) Prior year numbers are adjusted for the Reverse Share Split.

LEASES (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Schedule of Lease, Cost


	Financial Statement Classification	Three Months Ended September 30, 2023		Nine Months Ended September 30, 2023
Operating lease costs:
Fixed lease costs	Operating expenses	$	171	$	530
Total lease costs		$	171	$	530

Schedule of Lessee, Operating Lease, Liability, Maturity

The following table shows our undiscounted future fixed payment obligations under our recognized operating leases and a reconciliation to the operating lease liabilities as of September 30, 2023:


Leases and a reconciliation to the operating lease liabilities as of September 30, 2023
Remainder of Year 2023	$	183
2024	370
2025	107
2026	114
2027	113
Thereafter	84
Total future fixed operating lease payments	$	971

Less: Imputed interest	$	93
Total operating lease liabilities	$	878

Weighted-average remaining lease term - operating leases	2.89
Weighted-average discount rate - operating leases	8.0		%

DISCONTINUED OPERATIONS (Tables)

9 Months Ended

Sep. 30, 2023

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations


		Three Months Ended September 30,				Nine Months Ended September 30,
		2023		2022		2023		2022
Revenue, net		$	—	$	438	$	551	$	1,178



Cost of sales		—		(1,456)		—		(3,929)
Gross profit (loss)		—		(1,018)		551		(2,751)
Expenses
General and administrative		584		645		1,430		3,496
Restructuring expenses		—				—		30
Depreciation and amortization		—		203		—		613
Total expenses		584		848		1,430		4,139

Loss from operations		(584)		(1,866)		(879)		(6,890)

Interest (income) expense		14		7		33		24
Gain on sale of assets	—	(2,778)		—		(2,825)
Foreign exchange loss		48		99		44		275
Other income, net		(1)		—		—		—

Net gain (loss)		$	2,133	$	(1,972)	$	1,869	$	(7,189)

BASIS OF PRESENTATION - Narrative (Details) $ in Thousands	Aug. 24, 2023	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split conversion ratio	0.3333
Cash and cash equivalents		$ 6,472	$ 12,449

FAIR VALUE MEASUREMENTS - Fair Value Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Investment – Cansativa	$ 1,896	$ 5,679
Total Assets	1,896	5,679
Loans and borrowings	1,336	1,530
Warrant liability	108	113
Total Liabilities	1,444	1,643
Level 1
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Investment – Cansativa	0	0
Total Assets	0	0
Loans and borrowings	0	0
Warrant liability	0	0
Total Liabilities	0	0
Level 2
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Investment – Cansativa	0	0
Total Assets	0	0
Loans and borrowings	1,336	1,530
Warrant liability	0	0
Total Liabilities	1,336	1,530
Level 3
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Investment – Cansativa	1,896	5,679
Total Assets	1,896	5,679
Loans and borrowings	0	0
Warrant liability	108	113
Total Liabilities	$ 108	$ 113

FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Schedule of Equity Method Investments [Line Items]
Impairment loss	$ 3,705	$ 0	$ 3,705	$ 0
Cansativa
Schedule of Equity Method Investments [Line Items]
Impairment loss	$ 3,705		$ 3,705

FAIR VALUE MEASUREMENTS - Summary of Changes in Fair Value of the Company’s Level 3 Investments (Details) - Equity Method Investments - Level 3 - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 5,777	$ 5,753	$ 5,679
Change in value due to foreign exchange gain	(176)	24	74
Impairment loss	(3,705)
Ending balance	$ 1,896	$ 5,777	$ 5,753

FAIR VALUE MEASUREMENTS - Change in Fair Value (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Changes of Fair Value of Warrant Liabilities [Roll Forward]
Change in fair value of warrant liability				$ (5)	$ (2,009)
Private warrant
Changes of Fair Value of Warrant Liabilities [Roll Forward]
Warrant liability, beginning of period	$ 168	$ 157	$ 113	113
Change in fair value of warrant liability	(60)	11	44
Warrant liability, end of period	$ 108	$ 168	$ 157	$ 108

FAIR VALUE MEASUREMENTS - Warrant Assumptions (Details)	Sep. 30, 2023 $ / shares	Dec. 31, 2022 $ / shares
Risk-free interest rate
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input	0.0498	0.0423
Expected volatility
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input	1.60	1.05
Share Price
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input	0.12	0.31
Exercise Price
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, measurement input	11.50	11.50

INVENTORIES, NET - Components (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Inventory [Line Items]
Raw materials	$ 1,213		$ 1,213		$ 1,204
Total	7,709		7,709		8,399
Inventory provision	264	$ 555	591	$ 1,103
Harvested Cannabis And Extracts
Inventory [Line Items]
Work in progress	279		279		21
Cannabis Extracts
Inventory [Line Items]
Finished goods	5,832		5,832		6,703
Other
Inventory [Line Items]
Finished goods	$ 385		$ 385		$ 471

PREPAID, DEPOSITS AND OTHER RECEIVABLES - Components of Prepaids and Advances (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Prepaid and advances	$ 765	$ 650
Indirect tax receivables	1,080	2,007
Deposits	96	51
Prepaids, deposits and other receivables	$ 1,941	$ 2,708

INVESTMENTS - Narrative (Details) € / shares in Units, $ in Thousands				1 Months Ended				3 Months Ended		9 Months Ended
	Oct. 17, 2023 USD ($) shares	Oct. 17, 2023 EUR (€) shares	Dec. 21, 2018 EUR (€)	Apr. 30, 2022 USD ($) shares	Apr. 30, 2022 EUR (€) shares	Dec. 31, 2020 USD ($)	Jan. 31, 2019 EUR (€)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2020 € / shares	Dec. 01, 2020	Nov. 30, 2020	Sep. 30, 2020 EUR (€)	Sep. 30, 2019 USD ($) shares	Sep. 30, 2019 EUR (€) shares	Dec. 21, 2018 USD ($) tranche shares	Dec. 21, 2018 EUR (€) tranche € / shares shares
Summary of Investment Holdings [Line Items]
Investment – Cansativa \| $								$ 1,896		$ 1,896			$ 5,679
Gain (loss) on investment \| $								0	$ 0	0	$ 6,851
Equity method investments sold amount \| $										0	2,498
Impairment loss \| $								3,705	$ 0	3,705	0
Seed Financing Round \| Cansativa
Summary of Investment Holdings [Line Items]
Shares issued (in shares) \| shares																				3,096	3,096
Investments, fully diluted pre-money valuation																					€ 8,500,000
Preferred Shares \| Cansativa
Summary of Investment Holdings [Line Items]
Shares issued, price per share (Euro per share) \| € / shares														€ 543.31
Preferred Shares \| Seed Financing Round \| Cansativa
Summary of Investment Holdings [Line Items]
Shares issued, price per share (Euro per share) \| € / shares																					€ 322,970
Cansativa
Summary of Investment Holdings [Line Items]
Percentage of interest held (as a percent)				7.60%
Gain (loss) on investment \| $						$ 211					$ 6,851
Sale of stock, number of shares issued/sold in transaction (in shares) \| shares				1,586	1,586
Equity method investments sold amount					€ 2,300,000
Equity method investment, gain recognized \| $				$ 1,983
Equity method investment, additional gain (loss) recognized \| $				$ 4,868
Impairment loss \| $								$ 3,705		$ 3,705
Cansativa \| Subsequent Event
Summary of Investment Holdings [Line Items]
Sale of stock, number of shares issued/sold in transaction (in shares) \| shares	3,648	3,648
Equity method investments sold amount	$ 1,900	€ 1,800,000
Cansativa \| Cansativa, Employee Stock Ownership Plan (ESOP)
Summary of Investment Holdings [Line Items]
Shares issued (in shares) \| shares				992
Cansativa \| Cansativa \| Subsequent Event
Summary of Investment Holdings [Line Items]
Sale of stock, number of shares issued/sold in transaction (in shares) \| shares	3,582	3,582
Cansativa \| Tranche One
Summary of Investment Holdings [Line Items]
Investments, gross																					€ 1,000,000
Cansativa \| Seed Financing Round
Summary of Investment Holdings [Line Items]
Investments, net																					€ 7,000,000
Number of investment tranches \| tranche																				3	3
Percentage of interest held (as a percent)																				10.53%	10.53%
Payments to acquire investments			€ 3,100				€ 996,820
Share price (Euro per share) \| € / shares																					€ 1.00
Investment – Cansativa																				$ 1,075	€ 999,920
Investments, initial amount																					3,100
Investments, capital reverse payment																					996,820
Investments, additional																		$ 722	€ 650,000
Investments, additional, shares (in shares) \| shares																		2,138	2,138
Investments, consideration transferred, net assets (as a percent)																		16.60%	16.60%
Net assets																			€ 1,233,000
Goodwill																			€ 1,122,000
Cansativa \| Seed Financing Round \| Cansativa, Employee Stock Ownership Plan (ESOP)
Summary of Investment Holdings [Line Items]
Percentage of interest held (as a percent)															15.80%	16.59%
Cansativa \| Seed Financing Round \| Tranche One
Summary of Investment Holdings [Line Items]
Investments, gross																				$ 1,075	999,920
Cansativa \| Seed Financing Round \| Tranche Two
Summary of Investment Holdings [Line Items]
Investments, gross																	€ 0				3,000,000
Gain (loss) on investment \| $												$ (370)
Cansativa \| Seed Financing Round \| Tranche Three
Summary of Investment Holdings [Line Items]
Investments, gross																					€ 3,000,000
Cansativa \| Common Stock
Summary of Investment Holdings [Line Items]
Number of shares registered and fully paid-in capital (in shares) \| shares																				26,318	26,318
Cansativa \| Preferred Shares \| Series B Preferred Stock
Summary of Investment Holdings [Line Items]
Shares issued (in shares) \| shares				10,184
Cansativa \| Preferred Shares \| Seed Financing Round
Summary of Investment Holdings [Line Items]
Percentage of interest held (as a percent)														14.22%	15.80%

INTANGIBLE ASSETS, NET - Narrative (Details)	3 Months Ended		9 Months Ended		12 Months Ended
INTANGIBLE ASSETS, NET - Narrative (Details)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets	$ 167,000	$ 191,000	$ 533,000	$ 573,000
Indefinite-lived Intangible Assets [Line Items]
Impairment of intangible assets, finite-lived			0
Intangible asset impairment			0	19,000,000
Deferred income tax (recovery)	0	$ (6,650,000)	0	$ (6,650,000)	$ 6,650,000
Indefinite-lived intangible assets	$ 0		$ 0		0
Licenses
Indefinite-lived Intangible Assets [Line Items]
Intangible asset impairment					19,000,000
Indefinite-lived intangible assets					$ 19,000,000
Licenses \| Measurement Input, Weighted Average Cost of Capital \| Discounted Future Cash Flow
Indefinite-lived Intangible Assets [Line Items]
Intangible assets, measurement input					0.24
Herbal Brands, Inc.
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired						$ 7,091,000

INTANGIBLE ASSETS, NET - Components of Intangible Assets (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 7,091,000		$ 7,091,000
Accumulated Amortization	4,270,000		3,737,000
Total	2,821,000		3,354,000
Indefinite-lived Intangible Assets [Line Items]
Licenses	0		0
Impairment Charge	0	$ (19,000,000)
Gross Carrying Amount			7,091,000
Accumulated Amortization	4,270,000		3,737,000
Net Carrying Amount	2,821,000		3,354,000
Licenses
Indefinite-lived Intangible Assets [Line Items]
Licenses			19,000,000
Impairment Charge			(19,000,000)
Customer contracts
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	925,000		925,000
Accumulated Amortization	925,000		925,000
Total	$ 0		$ 0
Weighted- Average Useful Life (in Years)	0 years		0 years
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	$ 925,000		$ 925,000
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,000,000		1,000,000
Accumulated Amortization	767,000		669,000
Total	$ 233,000		$ 331,000
Weighted- Average Useful Life (in Years)	2 years 7 months 6 days		3 years
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	$ 767,000		$ 669,000
Customer list
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	650,000		650,000
Accumulated Amortization	574,000		478,000
Total	$ 76,000		$ 172,000
Weighted- Average Useful Life (in Years)	7 months 6 days		1 year 3 months 18 days
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	$ 574,000		$ 478,000
Trade name
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	4,516,000		4,516,000
Accumulated Amortization	2,004,000		1,665,000
Total	$ 2,512,000		$ 2,851,000
Weighted- Average Useful Life (in Years)	5 years 7 months 6 days		6 years 3 months 18 days
Indefinite-lived Intangible Assets [Line Items]
Accumulated Amortization	$ 2,004,000		$ 1,665,000

INTANGIBLE ASSETS, NET - Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023	$ 167
2024	585
2025	542
2026	482
2027	452
Thereafter	593
Total	$ 2,821	$ 3,354

PROPERTY, PLANT AND EQUIPMENT, NET - Components (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 21,141	$ 21,083
Less: accumulated depreciation	(8,389)	(7,120)
Property, plant and equipment, net	12,752	13,963
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,806	1,806
Building & warehouse
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,768	7,658
Laboratory equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	6,496	6,416
Agricultural equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,480	1,477
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,433	1,397
Furniture & appliances
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	794	785
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	106	240
Other
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 1,258	$ 1,304

DEBT - Components of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Loans and borrowings, current portion	$ 477	$ 465
Loans and borrowings, non-current portion	859	1,065
Total debt	$ 1,336	$ 1,530

DEBT - Other Borrowings (Details) € in Thousands, $ in Thousands, $ in Thousands	1 Months Ended	3 Months Ended						9 Months Ended
	Jan. 31, 2021 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Sep. 30, 2023 COP ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2022 COP ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 EUR (€)	Sep. 30, 2023 COP ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2022 COP ($)	Sep. 30, 2023 EUR (€)	Sep. 30, 2023 COP ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Dec. 31, 2022 COP ($)	Jan. 31, 2021 EUR (€)
Debt Instrument [Line Items]
Long-term debt		$ 1,336						$ 1,336								$ 1,530
Portugal Debt \| Foreign Line of Credit \| Clever Leaves Portugal Unipessoal LDA
Debt Instrument [Line Items]
Debt instrument, face amount	$ 1,213																		€ 1,000
Interest expense, debt		12	€ 11		$ 7	€ 7		33	€ 31		$ 24	€ 22
Repayments of debt		68	€ 63		63	€ 63		201	€ 188		200	€ 188
Long-term debt		604						604						€ 563		1,076	€ 875
Portugal Debt \| Foreign Line of Credit \| Clever Leaves Portugal Unipessoal LDA \| Euro Interbank Offered Rate (Euribor)
Debt Instrument [Line Items]
Basis spread on variable rate	3.00%
Coloumbia Debt \| Foreign Line of Credit \| Ecomedics S.A.S.
Debt Instrument [Line Items]
Debt instrument, face amount		1,295						1,295							$ 5,305,800
Interest expense, debt		21		$ 53,145	$ 2		$ 7,809	64		$ 160,245	67		$ 259,144
Repayments of debt								53		$ 222,978	$ 213		$ 875,864
Long-term debt		$ 732						$ 732							$ 2,967,844	$ 725		$ 3,471,576
First required payment term								6 months	6 months	6 months
Coloumbia Debt \| Foreign Line of Credit \| Ecomedics S.A.S. \| Minimum
Debt Instrument [Line Items]
Interest rate (as a percent)		10.96%						10.96%						10.96%	10.96%
Coloumbia Debt \| Foreign Line of Credit \| Ecomedics S.A.S. \| Maximum
Debt Instrument [Line Items]
Interest rate (as a percent)		12.25%						12.25%						12.25%	12.25%

CAPITAL STOCK - Common Shares (Details) - shares	Sep. 30, 2023	Aug. 24, 2023	Aug. 23, 2023	Dec. 31, 2022
Equity [Abstract]
Common stock, shares issued (in shares)	1,726,145			1,454,559
Common stock, shares outstanding (in shares)	1,726,145	1,500,000	45,700,000	1,454,559

CAPITAL STOCK - Reverse Share Split (Details) $ in Thousands		3 Months Ended	9 Months Ended
	Aug. 24, 2023 shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($)	Aug. 23, 2023 shares	Dec. 31, 2022 shares
Class of Warrant or Right [Line Items]
Reverse stock split conversion ratio	0.3333
Common stock, shares outstanding (in shares) \| shares	1,500,000	1,726,145	1,726,145		45,700,000	1,454,559
Proceeds from issuance of shares			$ 1,340	$ 27,686
Equity issuance costs			$ 199	$ 1,345
At-the Market
Class of Warrant or Right [Line Items]
Number of shares issued/sold in transaction (in shares) \| shares		201,912	253,898
Consideration received on transaction		$ 824	$ 1,140
Proceeds from issuance of shares		902	1,340
Equity issuance costs		$ 78	$ 200

CAPITAL STOCK - Equity Distribution Agreement (Details)	Jan. 14, 2022 USD ($)
Equity Distribution Agreement
Subsidiary, Sale of Stock [Line Items]
Sale of stock, authorized offering amount	$ 50,000,000

CAPITAL STOCK - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Aug. 24, 2023
Class of Warrant or Right [Line Items]
Exercise price (USD per share)					$ 345
Redemption price of outstanding warrants (USD per share)	$ 0.01		$ 0.01
Adverse effect to holders, amendment, percentage of approval (as a percent)	50.10%		50.10%
Gain (loss) on remeasurement of warrant liability	$ 60	$ 196	$ 5	$ 2,009
Common Stock
Class of Warrant or Right [Line Items]
Number of trading days where price is exceeded			20 days
Number of consecutive trading days where price is exceeded			30 days
Common Stock \| Minimum
Class of Warrant or Right [Line Items]
Share price (USD per share)	$ 540.00		$ 540.00
Warrant
Class of Warrant or Right [Line Items]
Warrant, outstanding (in shares)	12,877,361		12,877,361
Private Placement
Class of Warrant or Right [Line Items]
Warrant, outstanding (in shares)	4,900,000		4,900,000

GENERAL AND ADMINISTRATION - Components (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
General and Administrative Expense [Abstract]
Salaries and benefits	$ 2,263	$ 2,781	$ 7,464	$ 9,719
Office and administration	736	1,096	2,168	3,169
Professional fees	667	495	2,933	2,893
Share based compensation	52	958	954	2,606
Rent	178	196	564	627
Other	259	(84)	244	(149)
Total	$ 4,155	$ 5,442	14,327	18,865
Freight-out Cost			$ 464	$ 454

RESTRUCTURING EXPENSE - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
RESTRUCTURING EXPENSE - Narrative (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring expenses	$ 0	$ (82,000)	$ 0	$ 3,761,000

SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 52	$ 958	$ 954	$ 2,606
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	7	66	820	336
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ 45	$ 892	$ 134	$ 2,270

SHARE-BASED COMPENSATION - Activity of Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Stock Options
Outstanding, beginning balance (in shares)	13,619
Forfeited (in shares)	(479)
Expired (in shares)	(4,222)
Outstanding, ending balance (in shares)	8,918	13,619
Vested and expected to vest (in shares)	8,576
Vested and exercisable (in shares)	7,731
Weighted-Average Exercise Price
Outstanding, beginning (USD per share)	$ 233.46
Forfeited (USD per share)	336.36
Expired (USD per share)	320.87
Outstanding, ending (USD per share)	157.03	$ 233.46
Vested and expected to vest (USD per share)	151.33
Vested and exercisable (USD per share)	$ 123.73
Weighted-Average Remaining Contractual Term (Years) and Aggregate Intrinsic Value
Outstanding term	1 year 6 months 7 days	2 years 6 months 21 days
Vested and expected to vest term	1 year 6 months 21 days
Vested and exercisable term	1 year 14 days
Outstanding aggregate intrinsic value	$ 0	$ 0
Vested and expected to vest	0
Vested and exercisable	$ 0

SHARE-BASED COMPENSATION - Narrative (Details) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($) installment $ / shares shares	Dec. 31, 2022 USD ($)
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cost not yet recognized, amount \| $	$ 166	$ 392
Cost not yet recognized, period for recognition	11 months 12 days	1 year
Market-based Restricted Share Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) \| shares	0
Number of annual vesting installments \| installment	4
Market-based Restricted Share Units \| Installment, One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days where price is exceeded	20 days
Number of consecutive trading days where price is exceeded	30 days
Market-based Restricted Share Units \| Installment, Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of trading days where price is exceeded	20 days
Number of consecutive trading days where price is exceeded	30 days
Market-based Restricted Share Units \| Minimum \| Installment, One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (USD per share)	$ 12.50
Market-based Restricted Share Units \| Minimum \| Installment, Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share price (USD per share)	$ 15.00

SHARE-BASED COMPENSATION - Activity of Restricted Stock Units (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Time-based Restricted Share Units
Restricted Share Units
Non-vested, beginning balance (in shares) \| shares	45,566
Granted (in shares) \| shares	45,251
Vested (in shares) \| shares	(18,108)
Canceled/forfeited (in shares) \| shares	(5,602)
Non-vested, ending balance (in shares) \| shares	67,107
Weighted-Average Grant Date Fair Value
Non-vested, beginning price (USD per share) \| $ / shares	$ 105.05
Granted (USD per share) \| $ / shares	7.49
Vested (USD per share) \| $ / shares	88.96
Canceled/forfeited (USD per share) \| $ / shares	43.38
Non-vested, ending price (USD per share) \| $ / shares	$ 48.75
Market-based Restricted Share Units
Restricted Share Units
Non-vested, beginning balance (in shares) \| shares	17,632
Granted (in shares) \| shares	0
Vested (in shares) \| shares	(15)
Expired (in shares) \| shares	(71)
Canceled/forfeited (in shares) \| shares	(3,874)
Non-vested, ending balance (in shares) \| shares	13,672
Weighted-Average Grant Date Fair Value
Non-vested, beginning price (USD per share) \| $ / shares	$ 384.03
Granted (USD per share) \| $ / shares	0
Vested (USD per share) \| $ / shares	274.52
Expired (USD per share) \| $ / shares	272.58
Canceled/forfeited (USD per share) \| $ / shares	393.29
Non-vested, ending price (USD per share) \| $ / shares	$ 382.11

REVENUE - Narrative (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Deferred revenue, current	$ 437,000	$ 1,072,000
Deferred revenue, noncurrent	$ 0	$ 0

SEGMENT REPORTING - Narrative (Details)	9 Months Ended
SEGMENT REPORTING - Narrative (Details)	Sep. 30, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments	2

SEGMENT REPORTING - Net Sales and Segment Profit (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Segment net sales	$ 3,820	$ 2,867	$ 12,779	$ 12,008
Segment loss	1,942	1,299	6,902	6,373
Non-cash share-based compensation			(954)	(2,606)
Depreciation and amortization	(290)	(305)	(750)	(950)
Goodwill impairment		(19,000)		(19,000)
Loss from operations	(3,377)	(24,324)	(10,682)	(39,392)
Loss on debt extinguishment, net	0	0	0	2,263
Gain on remeasurement of warrant liability	(60)	(196)	(5)	(2,009)
Gain on investment	0	0	0	(6,851)
Impairment investment	3,705	0	3,705	0
Foreign exchange loss	275	669	297	1,144
Interest and amortization of debt issuance cost	5	(58)	23	2,696
Other (income) expense, net	(31)	102	(19)	111
Loss before income taxes and equity investment loss	(7,271)	(24,841)	(14,683)	(36,746)
Operating Segments
Segment Reporting Information [Line Items]
Segment net sales	3,820	2,867	12,779	12,008
Segment loss	(1,909)	(2,637)	(4,643)	(10,035)
Operating Segments \| Cannabinoid
Segment Reporting Information [Line Items]
Segment net sales	1,442	613	4,537	3,166
Segment loss	(2,225)	(2,732)	(6,237)	(11,144)
Operating Segments \| Non-Cannabinoid
Segment Reporting Information [Line Items]
Segment net sales	2,378	2,254	8,242	8,842
Segment loss	316	95	1,594	1,109
Other
Segment Reporting Information [Line Items]
Unallocated corporate expenses	(1,706)	(1,424)	(5,835)	(6,801)
Non-cash share-based compensation	(52)	(958)	(954)	(2,606)
Depreciation and amortization	290	(305)	750	(950)
Goodwill impairment	0	(19,000)	0	(19,000)
Loss from operations	$ (3,377)	$ (24,324)	$ (10,682)	$ (39,392)

SEGMENT REPORTING - Revenues by Channel (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenue, net	$ 3,820	$ 2,867	$ 12,779	$ 12,008
Mass retail
Segment Reporting Information [Line Items]
Revenue, net	2,618	1,570	8,133	6,065
Distributors
Segment Reporting Information [Line Items]
Revenue, net	923	927	3,738	4,250
Specialty, health and other retail
Segment Reporting Information [Line Items]
Revenue, net	107	282	361	1,234
E-commerce
Segment Reporting Information [Line Items]
Revenue, net	$ 172	$ 88	$ 547	$ 459

SEGMENT REPORTING - Revenues by Country (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenue, net	$ 3,820	$ 2,867	$ 12,779	$ 12,008
United States
Segment Reporting Information [Line Items]
Revenue, net	2,378	2,228	8,242	8,736
Israel
Segment Reporting Information [Line Items]
Revenue, net	0	0	600	704
Australia
Segment Reporting Information [Line Items]
Revenue, net	685	77	1,392	445
Brazil
Segment Reporting Information [Line Items]
Revenue, net	507	249	1,778	1,169
Germany
Segment Reporting Information [Line Items]
Revenue, net	59	275	68	722
Other
Segment Reporting Information [Line Items]
Revenue, net	$ 191	$ 38	$ 699	$ 232

SEGMENT REPORTING - Concentration Risk (Details) - Customer Concentration Risk

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Percentage of Revenues | Customer A

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

10.00%

20.00%

12.00%

13.00%

Percentage of Revenues | Customer B

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

Percentage of Revenues | Customer C

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

11.00%

^[1]

Percentage of Revenues | Customer D

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

Percentage of Revenues | Customer E

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

13.00%

^[1]

Percentage of Revenues | Customer F

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

Percentage of Revenues | Customer G

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

Percentage of Accounts Receivable | Customer A

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

18.00%

Percentage of Accounts Receivable | Customer B

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

20.00%

13.00%

Percentage of Accounts Receivable | Customer C

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

Percentage of Accounts Receivable | Customer D

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

^[1]

15.00%

Percentage of Accounts Receivable | Customer E

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

15.00%

10.00%

Percentage of Accounts Receivable | Customer F

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

16.00%

^[1]

Percentage of Accounts Receivable | Customer G

Segment Reporting Information [Line Items]

Concentration risk, percentage (as a percent)

13.00%

^[1]

[1]	denotes less than 10%

SEGMENT REPORTING - Long-lived Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 14,252	$ 15,463
Operating Segments \| Cannabinoid
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	14,163	15,308
Operating Segments \| Non-Cannabinoid
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 89	$ 155

NET INCOME (LOSS) PER SHARE - Computation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share [Abstract]
Loss from continuing operations	$ (7,271)	$ (18,191)	$ (14,683)	$ (30,160)
Income (loss) from discontinued operations	2,133	(1,972)	1,869	(7,189)
Net loss - basic	(5,138)	(20,163)	(12,814)	(37,349)
Net loss - diluted	$ (5,138)	$ (20,163)	$ (12,814)	$ (37,349)
Weighted-average common shares outstanding - basic (in shares)	1,580,456	1,407,419	1,513,575	1,221,107
Weighted-average common shares outstanding - diluted (in shares)	1,580,456	1,407,419	1,513,575	1,221,107
Loss from continuing operations -basic (USD per share)	$ (4.60)	$ (12.93)	$ (9.70)	$ (24.70)
Loss from continuing operations - diluted (USD per share)	(4.60)	(12.93)	(9.70)	(24.70)
Income (loss) from discontinued operations - basic (USD per share)	1.35	(1.41)	1.23	(5.90)
Income (loss) from discontinued operations - diluted (USD per share)	$ 1.35	$ (1.41)	$ 1.23	$ (5.90)

NET INCOME (LOSS) PER SHARE - Computation of Anti-dilutive Effect (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Aug. 24, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	108,704	110,665
Exercise price (USD per share)			$ 345
SAMA earnout shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	19,007	19,007
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	8,918	14,530
Unvested restricted share units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	80,779	77,128
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	17,777,361	17,840,951

LEASES - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease, payments	$ 202	$ 457	$ 621	$ 1,354
Minimum
Lessee, Lease, Description [Line Items]
Lessor, operating lease, renewal term	12 months		12 months
Maximum
Lessee, Lease, Description [Line Items]
Lessor, operating lease, renewal term	60 months		60 months

LEASES - Costs (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
LEASES - Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2023
Leases [Abstract]
Fixed lease costs	$ 171	$ 530
Total lease costs	$ 171	$ 530

LEASES - Undiscounted Future Fixed Payment Obligations (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Lease
Remainder of Year 2023	$ 183
2024	370
2025	107
2026	114
2027	113
Thereafter	84
Total future fixed operating lease payments	971
Less: Imputed interest	93
Total operating lease liabilities	$ 878
Weighted-average remaining lease term - operating leases	2 years 10 months 20 days
Weighted-average discount rate - operating leases	8.00%

DISCONTINUED OPERATIONS - Components (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Income (loss) from discontinued operations	$ 2,133	$ (1,972)	$ 1,869	$ (7,189)
Discontinued Operations, Held-for-sale \| Portugal Operation
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue, net	0	438	551	1,178
Cost of sales	0	(1,456)	0	(3,929)
Gross profit (loss)	0	(1,018)	551	(2,751)
General and administrative	584	645	1,430	3,496
Restructuring expenses	0		0	30
Depreciation and amortization	0	203	0	613
Total expenses	584	848	1,430	4,139
Loss from operations	(584)	(1,866)	(879)	(6,890)
Interest (income) expense	14	7	33	24
Gain on sale of assets	(2,778)	0	(2,825)
Foreign exchange loss	48	99	44	275
Other income, net	(1)	0	0	0
Income (loss) from discontinued operations	$ 2,133	$ (1,972)	$ 1,869	$ (7,189)

COMMITMENT AND CONTINGENCIES - Narrative (Details) - Terra Verde, Lda. € in Thousands	Jul. 01, 2023 EUR (€)
Loss Contingencies [Line Items]
Guarantor obligations, period	12 months
Guarantor obligations, amount	€ 500

SUBSEQUENT EVENTS - Narrative (Details) € in Thousands, $ in Thousands			1 Months Ended	9 Months Ended
	Oct. 17, 2023 USD ($) shares	Oct. 17, 2023 EUR (€) shares	Apr. 30, 2022 EUR (€) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Subsequent Event [Line Items]
Equity method investments sold amount \| $				$ 0	$ 2,498
Cansativa
Subsequent Event [Line Items]
Sale of stock, number of shares issued/sold in transaction (in shares)			1,586
Equity method investments sold amount \| €			€ 2,300
Subsequent Event \| Cansativa
Subsequent Event [Line Items]
Sale of stock, number of shares issued/sold in transaction (in shares)	3,648	3,648
Equity method investments sold amount	$ 1,900	€ 1,800
Subsequent Event \| Cansativa \| Cansativa
Subsequent Event [Line Items]
Sale of stock, number of shares issued/sold in transaction (in shares)	3,582	3,582
Subsequent Event \| Cansativa \| EIP Entrepreneurial Investment GmbH
Subsequent Event [Line Items]
Sale of stock, number of shares issued/sold in transaction (in shares)	66	66

Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Clever Leaves Charts.

Clever Leaves (NASDAQ:CLVR)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CLVR Clever Leaves Holdings Inc

News Clever Leaves Holdings Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

CLVR Clever Leaves Holdings Inc

News Clever Leaves Holdings Inc

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen